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ABSTRACT 
INHIBITION OF CATECHOL-O-METHYLTRANSFERASE (COMT) 
ENZYME ACTIVITY BY SOME PLANT-DERIVED                                
ALKALOIDS AND PHENOLS 
 
In this study, inhibition potentials of harmal seed alkaloids and olive leaf 
polyphenols were investigated on COMT catalyzed methylation reaction. Inhibition 
performances of natural alkaloids and polyphenolics whose purities were attempted to 
be increased by extraction and fractionation were compared with standards of these 
compounds and the best known COMT inhibitor, 3,5-dinitrocatechol.  
COMT enzyme inhibition experiments were performed with sentitive 
fluorometric method. In this method, Km values for SAM and aesculetin substrates were 
found as 3.5 ± 0.3 µM and 6.4 ± 0.4 µM, respectively. As a result of the inhibition 
study, the highest inhibitory effect is observed for harmine and harmaline rich fractions 
among harmal seed alkaloids. Inhibition constants indicating degree of competitiveness 
and noncompetitiveness (Ki and αKi) of the harmine fraction which has the highest 
inhibition performance were calculated as 0.15±0.07 µg/ml and 1.28±0.06 µg/ml, 
respectively. 
In the studies performed with standards of olive leaf polyphenols, while it was 
observed that rutin has inhibitory effect, oleuropein was found less effective. However, 
oleuropein rich fraction of olive leaf extract showed higher inhibitory effect than crude 
extract and rutin. It was also observed that polyphenolic extracts obtained from vitex, 
terebinth and mastic leaves showed high inhibition capacities, it was thought that 
fractionation should be performed for these plants. 
As a more general conclusion, it was revealed that harmal seed alkaloids and 
olive leaf fractions with high purity are promising natural COMT inhibitors. By 
performing this study, the kinetic inhibition constants of extracts, their fractions and 
standards could be determined and they could be reported into literature.  
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ÖZET 
KATEŞOL-O-METİLTRANSFERAZ (KOMT) ENZİM AKTİVİTESİNİN 
BİTKİLERDEN ELDE EDİLEN BAZI ALKALOİTLER                                  
VE FENOLLERLE ENGELLENMESİ 
 
Bu çalışmada, üzerlik tohumu alkaloitleri ve zeytin yaprağı polifenollerinin 
KOMT tarafından katalizlenen metillenme reaksiyonunu engelleyebilme potansiyelleri 
araştırılmıştır. Ekstraksiyon ve fraksiyonlama işlemleri ile saflıkları arttırılmaya 
çalışılmış alkaloitlerinin ve polifenollerinin KOMT enzim inhibisyonu performansları, 
bu bileşiklerin standartları ve bilinen en iyi KOMT inhibitörü olan 3,5-dinitrokateşol ile 
kıyaslanmıştır.  
KOMT enzim inhibisyon deneyleri, hassasiyeti yüksek ve ekonomik olan 
florometrik metot ile gerçekleştirilmiştir. Bu metotta metil verici ve metil alıcı substrat 
olarak kullanılan SAM ve Eskuletin için inhibitörsüz ortamdaki Km değerleri sırasıyla 
3,5 ± 0,3 µM ve 6,4 ± 0,4 µM olarak hesaplanmıştır. Toplam 18 adet standart, özüt ve 
fraksiyonun kullanıldığı inhibisyon çalışması sonucunda, üzerlik tohumu alkaloitleri 
arasından harmin ve harmalin alkaloitleri için en yüksek inhibisyon etkisi görülmüştür. 
İnhibisyon performansı en yüksek olan üzerlik tohumunun harmin fraksiyonunun 
kompetitiflik ve nonkompetitiflik derecelerine ait inhibisyon sabitleri (Ki ve αKi) 
sırasıyla 0,15±0,07 µg/ml ve 1,28±0,06 µg/ml olarak hesaplanmıştır. 
Zeytin yaprağı polifenollerinin standartları ile yapılan çalışmada rutinin KOMT 
enzimini inhibe etme özelliği görülürken oleuropeinin daha az etkili olduğu 
görülmüştür. Zeytin yaprağı özütünün oleuropeince zengin fraksiyonu ise oleuropein 
standardı, ham özüt ve rutine göre daha yüksek inhibisyon etkisi göstermiştir. Ayrıca, 
laden, menengiç ve sakız özütleri yüksek inhibisyon kapasitesine sahip olduklarından 
dolayı fraksiyonlama yapılması gereken bitki türleri olarak belirlenmiştir.  
Sonuç olarak, üzerlik tohumu alkaloitleri ve saflığı arttırılmış zeytin yaprağı 
fraksiyonları umut vaad eden doğal KOMT inhibitörleri oldukları tespit edilmiş ve 
inhibisyon kinetiği sabitleri literatüre kazandırılmıştır. Ayrıca, bu alkaloit ve polifenolik 
bazlı doğal bileşiklerin bilinen antioksidan ve antimikrobiyal özelliklerinin de olması 
nedeniyle çok fonksiyonlu bileşikler olarak bir çok sektörde kullanılabilecekleri 
anlaşılmıştır.  
 
 vi
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CHAPTER 1 
 
INTRODUCTION 
 
 Catechol O-methyltransferase (COMT) enzyme catalyzes methylation of the O-
hydroxyl groups in the structure of catechol by using S-(5'-Adenosyl)-L-methionine 
(SAM) as the methyl source (Mannistö et al., 1999). In mammalians, COMT presents in 
brain and peripheral tissues. The highest activity of COMT exists in liver, kidney and 
gastrointestinal tract (stomach-bowel) in rats and humans (Guldberg et al., 1975). 
COMT enzyme presents in its soluble form in many tissues but mainly bound to the 
membrane in the human brain. Primary physiological function of COMT enzyme is 
deactivation of catechols in and out of the cell having biological activity. 
Catecholestrogens, catecholamine neurotransmitters (dopamine, norepinephrine 
and epinephrine) and 3-(3,4-dihydroxyphenyl)-L-alanine) L-DOPA (levodopa), are the 
important substrates of the COMT. Among these, dopamine and levodopa, are known as 
in relationship with each other and the most important substrates. L-DOPA synthesized 
through hydroxylation of tyrosine in the sympathetic neuron terminals and adrenal 
glands, transfroms to 2-(3,4-dihydroxyphenyl)-ethylamine (dopamine) as a result of the 
reaction catalyzed by a pyridoxal phosphate enzyme dopa decarboxylase. 
Destruction of the dopaminergic neurons in the brain leads to the lack of 
dopamine and cause the starting of symptoms of the Parkinson disease. During 
pharmacological therapy, by taking of levodopa with dopa decarboxylase inhibitors, 
peripheral metabolism of levodopa is reduced thereby dopamine level in the brain can 
be increased (Bonifati et al., 1999; Dingemanse, 1997). Moreover, use of COMT 
inhibitors together with the levodopa and dopa carboxylase inhibitors plays a significant 
role in the therapy of the disease (Singh et al., 2007; Lerner et al., 2003). 
Among the COMT inhibitors that have been developed since 1960s, inhibitors 
that have been used clinically such as entacapone and tolcapone are known as the 
synthetic nitrocatechol compounds. Human liver besides being one of the most 
important tissue where compounds containing these types of catechols are metabolized, 
is one of organs where the highest activity of COMT presents (Vieria-Coelho et al., 
1996; Guldberg et al., 1975). Since the cytotoxic effects of the nitrocatecholic inhibitors 
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used in the therapy of Parkinson disease are known, the discovering and development of 
non-toxic natural inhibitors have ultimate importance. 
Moreover, it is known that in Parkinson patients, increase in the lipid 
peroxidation in the region of the brain known as substantia nigra (black matter) leads to 
increase in the production of free radicals (Sudha et al., 2003). In the researches, it has 
been stated that parkinsonism progresses due to increase in neuron degeneration 
resulted from the formation of free radicals. Thus, importance given to the use of 
natural compounds having antioxidant capacity as COMT inhibitors has increased 
(Chen et al., 2006; Esposito et al., 2002; Chiueh et al., 2000). 
Phytochemicals that are the indispensable chemicals of the traditional medicine 
and can be metabolized easily in the body are known have less toxic effects. Besides, 
due to that phytochemicals have antioxidant, antimicrobial and antitumour activities, 
they have been used increasingly in the modern therapy. Recently, the studies on the 
utilization of natural compounds in therapy of neurodegenarative diseases have gained 
importance. (Chen et al., 2005; Perry et al., 1999). In literature, for the therapy of 
Parkinson disease, utilization of many plant species that are rich in alkaloids and 
polyphenolics as especially COMT inhibitors has been investigated and the results have 
been reported. 
Alkaloids are compounds that can be biologically synthesized and have several 
pharmacological activities. Since the ancient times, they are not only used as medicine 
but also as a source of madder. Several kinds of these compounds that structurally 
contain nitrogen exist in nature. Tropane, ergot, and indole alkaloids are classes that are 
widely known and are usually used for narcotic purposes. The harmal plant (Peganum 
harmala), which is rich in one of the subclass of indole alkaloids that are β-carboline 
derived alkaloids, is a plant belonging to the wild cummin (zygophyllaceae) family. It is 
known that the harmal has been used for pharmaceutical purposes in ancient Greek and 
India as well as it is used today in modern medicine for worm omitting and narkotic 
puposes and as stimulant on the central nervous system. In the seeds of the harmal, 
alkaloids including harmaline, harmine, harmalol and harmol, and etheric oils present. 
In the studies on the harmal, it has been revealed that the harmal alkaloids prevent the 
degeneration of acetylcholine and dopamine by inhibiting acetylcholine esterase 
(AChE) and monoamin oxidase (MAO) enzymes that have important roles on the 
metabolic pathways of the Parkinson disease (Theodore et al., 1999). Furhermore, a red 
dye can be extracted from its seeds (Akalın, 2003). 
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Another important class of the phytochemicals is known as polyphenols. Similar 
to alkaloids, polyphenols have also been utilized in pharmaceutics, chemicals and food 
applications since ancient times and most of them have been extracted mainly from 
plants. 
Compounds such as oleuropein and rutin which majorly exist in the olive (Olea 
europaea) leaves and apigenin glycosides belong to the widest class of polyphenols and 
they are known as flavanoids. These subtances for which antimicrobial and antioxidant 
activities have been stated by the researches, can neutralize or delay the effects of the 
free radicals causing many diseases including hearth disease, cancer, diabetes, aging 
and cataract (Garcia et al., 2000). On account of these properties, it has been thought 
that they may prevent the free radicals formed upon neuron degeneration causing to the 
Parkinson disease and especially oleuropein ve rutin can inhibit the COMT enzyme. 
This study aims investigation of  effects of  olive leaf polyphenols such as 
oleuropein ve rutin having antioxidant, antimicrobial, anticarcinogenic and antiviral 
activities and of harmal seed alkaloids including harmaline, harmine, harmalol and 
harmol as COMT inhibitors. In accordance to this purpose, the extracts obtained from 
these plants are fractionated and  also performances of each fraction are examined as 
COMT inhibitors. The performances of the natural inhibitors are compared with those 
of the synthetic COMT inhibitors that are commercially used currently and have some 
adverse health effects. 
 
 
 
 
 
 
 
 
 4
CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1. Neurodegenerative Diseases  
 
 Neurodegenerative diseases, one of the matters that could not been illuminated 
by the medical science, involves many negative situations resulted from destruction of 
especially central nervous system (CNS) neurons and their chronic dysfunctions. 
Mitochondrial defects, protein aggregation, high metal concentration and oxidative 
stress are known as the most significant reasons for death and destruction of the neurons 
(Cavalli et al., 2008). 
Protein 
Aggregation High 
[Metal]
Oxidative 
Stress
Protein 
misfolding
Altered protein 
phosphorilation
Mitochondrial 
dysfunction
Neuronal Death
 
Figure 2.1. Factors resulting in neuron death and general impression mechanisms         
(Source: Cavalli et al., 2008). 
 
 
Many neurological disorders such as multiple sclerosis (MS), Alexander disease, 
amiyotrophic lateral sclerosis (ALS), bovine spongioform encephalopathy (BSE), 
Creutzfeldt-Jakob disease, schizophrenia, epilepsy and lethargy that are still under 
etiologic investigation occur in humans. Alzheimer and Parkinson diseases are known 
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as the most important diseases among the neurological disorders that are commonly 
seen at older ages as revealed by the researches (Institute of Neurodegenerative 
Diseases, 2009). Alzheimer disease is a kind of neurological disorder is characterized 
primarily by comprehension loss and dotage. In early periods of the Alzheimer disease, 
which begins with dotage generally above the age of 65 and progresses, symptoms such 
as loss in comprehension and memory are observed while symptoms such as speech 
disturbance, depression and mental instability are also frequently observed in the late 
periods (Houghton et al., 2005). 
 
2.1.1. Parkinson Disease 
 
Parkinson disease was first described in 1817 by an English surgeon Sir James 
Parkinson as a syndrome of trembling of muscles unwillingly (Zhu, 2004). From 
pathological point of view, although the etiology of Parkinson disease has not been 
explained clearly it is characterized as chronic and ascending disorders of the CNS 
neurons and known that it is caused by degeneration of dopaminergic neurons existing 
in the nucleus part of the midbrain called as substantia nigra pars compacta (SNpc). 
 
 
Figure 2.2. Important parts of brain. (*Pons: Mass consisted of CNS nerve cells and 
fibers in front of the cerebellum **Corpus Callosum: Center controlling 
generally paresis ve physical disorders) 
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In addition, since presence of neurons deposited in the cytoplasm called Lewy 
bodies and increased oxidative stress depending on increase in the reactive oxygen 
species in the midbrain lead to death of the dopamine producing neurons, they are 
shown amongst the causes of the disease (Houghton et al., 2005). The other important 
reasons of Parkinson disease related to these factors are known as; 
• Decrease in dopamine level in the brain,  
• Imbalance between neurotransmitters (Gamma-aminobutyric acid (GABA), 
Acetylcholine, Norepinephrine, Serotonin), 
• Formation of free radicals. 
Although Parkinson disease seen in many people commonly in elders, even 
rarely it has been observed also in people below the age of 40 (Houghton et al., 2005). 
Increase in tremors in arms and legs, muscular rigidity (dyskinesia), slowing down of 
movement (bradykinesia) and loss of balance as well as cognitive dysfunction and 
memory loss that are also seen in Alzheimer disease are known as clinical symptoms of 
Parkinson disease (Zhu, 2004; Dingemanse, 1997). In later stages of the disease, 
depression, impairment in speech, mental confusion, sleeping disorder, dotage, and 
constipation are observed as secondary symptoms (Polymeropoulos et al., 1996). 
 
2.1.2. Treatment Methods for Parkinson Disease 
 
Until the late of 1950s, memory loss and tremor have been known as common 
symptoms of many neurodegenerative disorders and the patients have generally been 
using common treatment methods and drugs against these symptoms.  
Currently, it has been partly possible to distinguish between neurodegenerative 
disorders that have not been treated yet exactly and specific drugs to each of them have 
been developed by also taking the advantage of the knowledge and experiences 
(Houghton et al., 2005). Various drugs developed for the treatment of Parkinson disease 
have been categorized into subclasses and these have been used clinically either solely 
or together depending on the stage of the disease. Furthermore, surgical operations have 
been applied for the treatment at later stages of the disease. 
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2.1.2.1. Pharmacotherapy (Drug Treatment) 
 
The commercially available drugs that control the various symptoms of 
Parkinson disease include: 
o Dopamine agonists (substances exhibiting similar effects of dopamine),  
o Levodopa/dopa decarboxylase inhibitors (benserazide, carbidopa),  
o Anticholinergic agents1,  
o Amantadine2, 
o Monoamine oxidase-B (MAO-B)3 inhibitors (selegiline), 
o Catechol O-methyltransferase (COMT) inhibitors (Nadeau, 1997).  
Although these drugs can not behave exactly as dopamine and can not supply the 
lack of dopamine which is the main reason of Parkinson disease, they can prevent the 
decrease and balance the levels of dopamine and acetylcholine in the brain. The drugs 
clinically used in the treatment of Parkinson disease can not treat the disease completely 
but can provide improvement by decreasing the symptoms observed in the patients 
(Nadeau, 1997).  
It is the most important criteria to determine the stage of the disease in selection 
of the drug that will be applied in the pharmacological treatment. Before deciding on 
any drug, the Parkinsonizm level of the patient must be determined. The algorithm for 
the treatment methods applied depending on the stage of the disease is shown in Figure 
2.3.  
 
 
 
 
 
1 Anticholinergic agents: substance or agent withstanding the effects of acetylcholine and paralyzing the 
glands and muscle elements inerved by the cholinergic fibres (atropine, scopolamine) 
2 Amantadine: compound (drug) which is known to have dopaminergic, adrenergic and slightly 
anticholinergic affects that diminishes the conditions such as nervousness, insomnia and anxiety as well 
as the Parkinsonism symptoms. 
3 Monoamine oxidase-B: Monoamine oxidase enzyme catalyzes the oxidation rection of the monoamines. 
It metabolizes amine neurotransmitters such as dopamine, norepinefrine and serotonin. This enzyme is 
present on the outer membrane of mitochondria and is synthesized by monoamine oxidase A gene. It has 
two types called MAO-A and MAO-B. Both are present in neurons and astroglias. MAO-A is present in 
liver, digestion system and plesanta as well as in central nervous system.  MAO-B is present mostly in 
blood platelets.  
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Figure 2.3. Algorithm for the treatment method of Parkinson disease depending on its 
stage 
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2.1.2.2. Surgical Operations 
 
Before the development of L-dopa which is the main drug for treatment of 
Parkinson disease, the patients have been subjected to surgical operations at early stages 
of the disease. As seen from the algorithm given in Figure 2.3, today surgery is the last 
choice at the stage where the drug treatment applied has no use in relief of the 
symptoms. The main purpose of the surgery is breaking off the nerve connections in 
thalamus1 and globus pallidus2 parts in the brain (Lozano et al., 1998). 
• Stereotaxic technique: It was firstly employed in 1950 before the development 
of L-dopa. This technique is used in neurosurgery and neuroradiology for the 
purpose of 3-dimensional radiographic and topographic investigations of the 
deep parts of the brain by means of an electrode inserted through a hole opened 
on the skull (Singh et al., 2007).  
• Pallidotomy: This technique firstly employed in 1940’s is still used for the 
surgical treatment of Parkinson disease (Lozano et al., 1998). In the application 
of pallidotomy, again a hole is opened through the skull and the globus pallidus 
part is burned by means of a heated wire inserted through the hole. Although this 
technique carries many risks, the symptoms of the disease can be alleviated by 
breaking off the connection of the dopamine circuit with the thalamus. After the 
pallidotomy application, the patients continue to take their drugs at the previous 
dosage (National Institute of Neurological Disorders and Stroke, 2009; National 
Parkinson Foundation, 2009; Singh et al., 2007).  
• Thalamotomy: Tthis technique carrying risks as much as pallidotomy was first 
applied in 1950’s. During application, lesions formed in the nucleus of the 
thalamus are removed using an extremely cold metal rod and thereby the 
tremblings of the patients are reduced (Lozano et al., 1998). 
• Stimulation of the Brain: In this technique, which was first practisized in 1997, 
the brain is stimulated by use of electrodes inserted in specific parts of the 
thalamus (Singh et al., 2007).  
 
1 Thalamus: Center which is present in the inner center of the brain controlling all senses except for the 
scent and responsible for transmission of knowledge to other control centers. 
2 Globus Pallidus: One of the important ganglions presents out of and above the thalamus including 
nerves responsible for transmission of movement, emotions and senses.  
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• Transplantation: In transplantation method, cells taken from medulla of the 
patient’s own adrenal gland are transplanted in place of the diseased cells 
(Parkinson’s Disease Society, 2009; Singh et al., 2007). 
Due to severity and intensity of the methods applied for the treatment of 
Parkinson disease including pharmaceutical therapy and surgery, they are still hot topics 
for the researchers. From this point, pathology, etiology, synthetic and natural treatment 
methods of the disease have been extensively investigated. 
 
2.1.3. Important Criteria in Drug Development for the Treatment of 
Parkinson Disease 
 
 Similar to the most of neurodegenerative diseases, difficulty in delivery of 
substances used as drug in the treatment of Parkinson disease to the specific parts of the 
brain is one of the most important problems encountered. Therefore, during drug 
discovery and development, structural characteristics and functions of the certain parts, 
naturally present in the structure of the brain where transition of chemical substances 
takes place, have been investigated. 
 
2.1.3.1. Blood-Brain Barrier 
 
Blood-Brain Barrier (BBB) is a highly specific barrier system that is consisted of 
epithel cells. Besides, it includes pericyte, astrocyte and neuronal cells in its structure 
(De Boer et al., 2007). Since the epithel cells in the form of segments that are attached 
to each other allow partial transition of the molecules, they provide most of selectivity 
to the barrier. The most vital function of the BBB that is responsible for the transition of 
molecules, DNA and enzymes is to protect the brain stability and to separate the brain 
cells from the blood (De Boer et al., 2007; Sumio, 2004). Moreover, BBB has functions 
of transition of agents that can be used in diagnosis and treatment of the neurological 
diseases and consequently transmission of those agents to the brain. 
Although dopamine, for which decrease in its level in the brain is the main 
reason of Parkinson disease, is a neurotransmitter that can not pass through the BBB, L-
dopa, which is known as the precursor of dopamine, can pass through the BBB 
(Dingemanse, 1997). Yet, since transition of most of the therapeutic molecules like 
dopamine and genes through the BBB in desired amounts cannot be allowed, it is a 
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criteria that should be taken into account during the drug development. The potential 
transport types through the BBB are explained by the known diffusion mechanisms in 
Figure 2.4 (De Boer et al., 2007). 
 
Epithel 
cellsMetabolism
Tight 
Junctions
Membrane
BRAIN
Brain cells (astrocytes, pericytes ve neurons)
Transport Types in the Blood-Brain Barrier
21 3 4 5 6
BLOOD
 
 
Figure 2.4. Possible transport types through BBB. (1. Lipophilic transport, 2. Ionic 
transfer, 3. Hydrophilic transport, 4. Transport with carriers, 5. Transport    
by adsorption, 6. Transport with receptors)  
 
 
2.1.3.2. Brain-Spinal Cord (Cerebrospinal) Fluid Barrier 
 
The fluid in the subaracnoid gap and in the spinal cord channel which is one of 
the brain membranes is called as cerebrospinal fluid (CSF). CSF is generally formed 
within the glomus of capillaries (coroid plexus) extended to specific regions on the wall 
of small voids (ventricules). CSF, which is a dynamic fluid, joins to the blood 
circulation through being absorbed by the veins in the brain. This liquid formed in the 
coroid plexus, plays an important role in the drug metabolism and transfer as well as in 
the cell regeneration and neuron transmission (De Boer et al., 2007; Zheng et al., 2004). 
Moreover, CSF helps the phase I-II and III enzymes present in the coroid plexus to 
preserve their activation (De Boer et al., 2007). 
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The activation of COMT, which is one of the important phase I-III enzymes as 
explained in detail in Section 2.1.4, and regulation of the metabolic reactions related to 
this enzyme are also controlled by CSF (Zheng et al., 2004).  
 
2.1.4. COMT Enzyme and Its Role in Parkinson Disease 
 
The drugs used in the treatment of neurodegenerative disorders are first adsorbed 
and then delivered to the specific targets in the body. The drugs reached to the target are 
metabolized and excreted (Lautala, 2000). The metabolic transformation of the drugs 
occurs through many enzymatic reactions. The enzymes taking part in the metabolic 
reactions are called as phase I-II and III enzymes. The phase I enzymes such as 
Cytochrome P-450 and MAO contribute to the oxidation, reduction and hydrolysis 
reactions and thereby the forms of the drugs that can bind to the related  functional 
groups are obtained (De Boer et al., 2007; Lautala, 2000). The phase II enzymes, mainly 
including glucuronozyl, glutathione, sulfo, acetyl and methyltransferases, catalyze the 
reactions required for the metabolizing of the conjugated forms of the drugs (Lautala, 
2000). As a result of these reactions, pharmacologically active compounds are formed. 
Stability of the formed active compounds and the microenvironment where they present 
is preserved by the phase III enzymes known as sodium-dicarboxylate, ascorbic acid, 
organic anion and cation carriers (De Boer et al., 2007). 
Catechol O-methyltransferase (COMT; EC 2.1.1.6), which is one of the phase II 
enzymes, present in kidney, liver and brain in mammalians. Furthermore, the activity of 
COMT was also observed in the gastrointestinal channel, muscles, erytrocytes, and in 
some organs and tissues (Reenilä, 1999; Guldberg et al., 1975). The COMT enzyme, 
which is coded by a single gene and different promoters, has two different forms having 
different amino acid chain numbers (Lotta et al., 1995). The activities of the soluble (S-
COMT) and membrane-bound (MB-COMT) forms change depending on their cellular 
distribution, sex and age (Bonifacio et al., 2007; Lautala, 2000; Gogos et al., 1998; De 
Santi et al., 1998).  
 S-COMT that present in humans and recombinant S-COMT isolated from rat 
exhibited structural similarities in 81% as revealed by the molecular biologists (Lautala, 
2000). Hence, in the studies on determination of COMT activity in vitro, recombinant 
S-COMT isolated from rat has been used. Firstly in 1994, Vidgren and co-workers 
studied the three dimensional structure of the complex that is formed by the enzyme and 
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its substrates and the inhibitor in order to elucidate the activity of recombinant S-COMT 
isolated from rat and molecular mechanism of the methylation reaction  (Bonifacio et al. 
2007; Lautala, 2000). According to the results of this study on the crystal structure of S-
COMT, complex β-sheets and eight α-helixes surrounding them are present in the 
center of the enzyme. This topology is also observed in other methyltransferases that 
use S-adenosyl-L-methionine (SAM) like DNA and RNA methyltransferases. Also, it 
was revealed that the catalytic region of the COMT enzyme is present at the center and 
on the surface of the giant protein structure (Bonifacio et al., 2007). In the catalytic 
region of the enzyme schematically illustrated in Figure 2.5, there are two distinct 
regions, the one where SAM binds and the other where catecholic substrate binds 
(Bonifacio et al., 2007). SAM, which is the methyl source, is buried in the structure at 
the catalytic region, while the other region, where the catecholic substrate binds, is in 
the space on the surface (Lautala, 2000). 
 
 
 
Figure 2.5. 3D representation of S-COMT isolated from rat. (3,5-DNC: 3,5-dinitro-
catechol (COMT inhibitor)) 
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The magnesium ion (Mg2+), which is used as cofactor by COMT, is coordinated 
by a water molecule, two aspartic acid residues (Asp141, Asp169), an asparagine 
residue (Asn170) and hydroxyl groups of the catechol molecule via hydrophobic forces 
(Bonifacio et al., 2007; Lautala, 2000). The giant protein structure of the enzyme is 
preserved by this coordination. The structurally important Mg2+ lowers the pKa values 
of the hydroxyl groups of the catecholic substrate and causes them to ionize faster 
(Lautala, 2000). One of the ionized hydroxyls is stabilized by forming a hydrogen bond 
to the negatively charged carboxyl group of the glutamic acid residue (Glu199) as 
shown in Figure 2.6. The other hydroxyl gives a proton to the lysine residue (Lys144) 
and breaks bond of the electron deficient methyl group of SAM (Bonifacio et al., 2007; 
Lautala, 2000). This reaction, which is explained by the nucleophilic substitution 
mechanism (SN2 type) shown in Figure 2.7, is completed by binding of the methyl 
group broken from the SAM to the proton-deficient hydroxyl group of the catecholic 
ring (Lautala, 2000). 
 
 
Figure 2.6. Catalytic region of S-COMT. 
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Figure 2.7. General mechanism of the COMT catalyzed methylation reaction.  
 
 
In the molecular level studies related to the COMT enzyme, the best known 
inhibitor of the enzyme 3,5-dinitrocatechol, has been used as the catecholic compound 
which are given in Figures 2.6 and 2.7. However, biologically active or xenobiotic 
endogenous and exogenous catecholic compounds are the substrates of physiological 
COMT and metabolized through O-methylation reaction (Bai et al., 2007; Kurkela et 
al., 2004; Erdal et al., 2002; Ruottinen et al., 1998; Lotta et al., 1995). The 
catecholamines (dopamine, epinephrine, norepinephrine), catecholestrogens (2 and 4-
hydroxyestradiol), L-dopa (levodopa) and ascorbic acid that can be methylated by 
COMT enzyme are the well-known endogenous catecholic substrates (Chen et al., 2005; 
Mannistö et al., 1999; Lotta et al., 1995). The exogenous catecholic substrates are 
known as compounds in our dietaries and some medicines such as triphenols, 
flavonoids, benserazide, carbidopa and dihydroxyphenyl serine (Bai et al., 2007; Chen 
et al., 2005; Lautala, 2000; Mannistö et al., 1999).  
These catecholic compounds, also used as substrates of COMT, are administered 
solely or in accompaniment to the other drugs as previously mentioned in the Section 
2.1.2.1. The metabolic roles of the COMT inhibitors, of catecholic compounds, 
especially of levodopa which can pass through the blood-brain barrier (BBB), and of 
aromatic L-aminoacid decarboxylase (AADC) and MAO-B inhibitors in the treatment 
of Parkinson disease are summarized in Figure 2.8. 
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Figure 2.8. Metabolic routes effective in Parkinson disease. 3-OMD: 3-O-methyldopa, 
Dopac: 3,4-dihydroxyphenylacetic acid, 3-MT: 3-methoxytyramine, HVA: 
homovanillic acid (Source: Dingemanse, 1997). 
 
 
It was previously stated in detail in the Section 2.1.1 that the deficiency of 
dopamine level in the brain (central) is one of the most important reasons of Parkinson 
disease. In the treatment of the disease, it was claimed that co-administration of 
compounds like carbidopa, which is used as the AADC inhibitor, with the COMT 
inhibitors leads to decrease in the peripheral dopamine level (Dingemanse, 1997). 
However, by this treatment method, the level of levodopa, which is the precursor of 
dopamine and can pass through the blood-brain barrier (BBB), can be increased and 
thereby the central dopamine level can be adjusted to the desired levels. In Figure 2.8, 
the reactions catalyzed by MAO-B and COMT enzymes causing transformation of the 
central dopamine are shown. From this point, during the treatment depending on the 
stages of disease, the MAO-B inhibitors such as selegiline is used in addition to the 
COMT inhibitors so that the central dopamine level can be adjusted at the desired level 
(Mannistö et al., 1992). 
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2.2. COMT Inhibitors 
 
Towards the end of 1950’s, the purification techniques have been improved and 
studies on discovery and development of inhibitor for the structurally-characterized 
COMT enzyme have been emerged. The standard substances used as COMT inhibitors 
or their chemically-synthesized forms can be classified into the groups based on their 
historical development. 
 
2.2.1. Synthetic Inhibitors  
 
2.2.1.1. First Generation COMT Inhibitors 
 
Pyrogallol which was invented by Axelrod and LaRoche in 1959 was defined as 
the first potential COMT inhibitor and has been used in the following years as the 
model inhibitor in the studies on the inhibitor development (Guldberg et al., 1975). The 
substances developed as the first generation inhibitors including gallic acid, caffeic acid, 
3`,4`-dihydroxy-2-methyl-propiophenon (U-0521), 2-hydroxyestrogen are the 
derivatives of pyrogallol and catechol (Bonifacio et al., 2007; Bailey et al., 2005). 
Among the non-catecholic substances, ascorbic acid, tropolone, 8-hydroxyquinoline 
derivatives, 3-hydroxylated pyrones and pyridones are also used as the first generation 
COMT inhibitors (Bonifacio et al., 2007; Mannistö et al., 1999). Furthermore, some 
flavonoids such as quercetin and rutin are also known as inhibitors of this class of 
inhibitors (Bonifacio et al., 2007). 
Although the first generation COMT inhibitors have high in vitro inhibition 
performances, results of the animal tests did not show the successful inhibition. These 
inhibitors with low in vivo inhibition properties and selectivity, with short efficacy 
periods and having toxicity could not been found a role in clinical applications 
(Mannistö et al., 1999; Dingemanse, 1997; Guldberg et al., 1975). 
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2.2.1.2. Second Generation COMT Inhibitors 
 
New COMT inhibitors most in nitrocatecholic structure were synthesized in the 
late 1980’s. As structurally shown in Figure 2.9, entacapone [OR-611; (E)-2-cyano-
N,N-diethyl-3-(3,4-dihydroxy-5-nitrocinnamide)], nitecapone [OR-462; 3-(3,4-
dihydroxy-5-nitro-benzylidine)-2,4-pentadion], tolcapone [Ro 40-7592; 4`-methyl-3,4-
dihydroxy-5-nitro-benzophenon], nebicapone [BIA 3-202; 1-(3,4-dihydroxy-5-
nitrophenyl)-2-phenyl-ethanone], some nitrobenzaldehydes and nitronoradrenalines are 
nitrocatecholic substances developed as second generation COMT inhibitors (Bonifacio 
et al., 2007; Loureiro et al.,  2006; Mannistö et al., 1999). Other than the nitrocatecholic 
inhibitors, the inhibitor coded as CGP 28014, a pyridine derivative, is also known as 
second generation COMT inhibitor (Mannistö et al., 1999; Dingemanse, 1997). 
 
 
Figure 2.9. Some second generation COMT inhibitors                                          
(Source: Bonifacio et al., 2007; Palma et al., 2006; Mannistö et al., 1999). 
 
 
The nitrocatecholic inhibitors are synthesized from the well-known synthetic 
COMT inhibitor 3,5-dinitrocatechol (3,5-DNC) compound. As shown in Figure 2.9, the 
synthesis is performed by binding of another functional group in place of one of the 
nitro groups which is present in orto and para positions of the catechol ring (generally 
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para position) in the structure of 3,5-DNC with respect to the same hydroxyl group 
(Bonifacio et al., 2007; Learmonth et al., 2002; Bäckstrom et al., 1989). The CGP 
28014 coded pyridine derivative inhibitor is obtained by addition of specific functional 
group after being transformed to pyridone (Waidmeier et al., 1990). 
Among the inhibitors with higher potential and selectivity as compared to the 
first generation inhibitors, nitecapone, entacapone and tolcapone are known as the 
second generation inhibitors which have been used clinically (Ruottinen et al., 1998; 
Dingemanse, 1997). It was reported that these inhibitors in nitrocatecholic structure are 
known as reversible and tight binding inhibitors of COMT (Bonifacio et al., 2007; 
Palma et al., 2006; Mannistö et al., 1999). The concentrations of nitecapone, entacapone 
and tolcapone required to decrease the peripheral COMT activity by 50 percent (IC50) 
were reported as 300 nM, 150 nM and 36 nM, respectively. The IC50 values of them for 
the brain COMT activity were found to be 10 nM, 20 nM and 0.3 nM, respectively 
(Bonifacio et al., 2007; Mannistö et al., 1999). These values indicated that the 
nitrocatecholic inhibitors were 1000 times more effective than the first generation 
inhibitors (Bonifacio et al., 2007). 
It was found that mode of action of nitecapone is primarily effective on 
duodenum so, its use in the treatment of Parkinson disease has been limited (Nissinen et 
al., 1988). Currently, the other potential COMT inhibitors (entacapone and tolcapone) 
are used in combination with MAO-B and AADC inhibitors, and levodopa (Singh et al., 
2007; Ruottinen et al., 1998; Dingemanse, 1997).  
According to the results of the studies on treatment methods applied to the 
Parkinsonians, entacapone showed high peripheral COMT inhibition, while tolcapone, 
which can pass through the blood-brain barrier, decreased the both central and 
peripheral COMT activity. Moreover, the efficacy period of tolcapone was found to be 
longer than that of entacapone almost twice (Bonifacio et al., 2007; Mannistö et al., 
1999; Ruottinen et al., 1998).  
Although new COMT inhibitors as effective and clinically applicable as these 
two compounds have not been developed yet, it is known that their use in high 
concentrations caused some toxic or carcinogenic effects on the liver (Singh et al., 
2007; Bonifacio et al., 2007; Mannistö et al., 1999; Ruottinen et al., 1998). The 
administration of tolcapone, which has higher hepatoxicity as compared to entacapone, 
has been banned in some countries (Europe and Canada) (Singh et al., 2007; Mannistö 
et al., 1999; Nissinen et al., 1992). 
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The researches on the development of catecholic based inhibitors with high 
selectivity have been going on in spite of the inhibitors in nitrocatecholic structure 
which are highly effective in inhibition but have significant adverse side effects.  
 
2.2.1.3. Last Generation – Non-typical COMT inhibitors 
 
According to the classification of the COMT inhibitors based on their historical 
development, CGP 28014 coded compound defined as a second generation inhibitor has 
been later included in the group of non-typical COMT inhibitors. This compound that is 
unsuccessful in in vitro COMT inhibition, it resulted in significant inhibition effect 
especially on the central COMT inhibition (Mannistö et al., 1999, 1992; Dingemanse, 
1997). However, studies on mode of action and toxicity of this compound have not been 
completed yet.   
Many COMT inhibitors included in this class are compounds that are 
structurally modified from the nitrocatecholics and are gained some specific properties 
(Bonifacio et al., 2007; Paulini et al., 2006).  
 
 
Figure 2.10. Some last generation COMT inhibitors. 
 
 
Bisubstrate inhibitors are synthesized as structures that can bind to the SAM and 
catechol binding regions in the active site of COMT enzyme and thereby it might 
prevent the interaction of the enzyme with its substrates that may lead to the disease 
(Paulini et al., 2006; Learmonth et al., 2005; Lerner et al., 2003). Among the bisubstrate 
inhibitors having several structurally-characterized derivatives, the in vitro IC50 value 
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for the [N-{(E)-3-[(2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-3,4-dihydroxytetrahydro-
furan-2-yl]prop-2-enyl}-2,3-dihydroxy-5-nitrobenzene-1-carboxa-mide] compound was 
found as 9 nM (Bonifacio et al., 2007; Lerner et al., 2003).  
The bifunctional inhibitors are formed through synthesis of two catechol rings, a 
nitro group is added to each. It was claimed that in vitro inhibition potentials of these 
types of compounds are higher than those of their analogs with single catechol ring 
(Bailey et al., 2005).   
On the other hand, in vivo data on the bisubstrate inhibitors as well as the 
bifunctional ones has not been confirmed, the mechanisms of them have not been 
elucidated and the toxicity studies have not been performed yet (Bonifacio et al., 2007). 
 
2.2.2. Natural Inhibitors 
 
During last years, researches on the potential utilization of some natural 
compounds that are generally obtained from plants (phytochemicals) in the treatment of 
neurodegenerative diseases have been increased. Since plant-based compounds can be 
metabolized easily in the body and have less side effects, their utilization in inhibition 
of enzymes catalyzing some metabolic reactions causing neurodegenerative diseases is 
extremely important (Perry et al., 1999).  
In the literature, within the large class of phytochemicals, studies on inhibition 
of AChE (acetylcholine esterase), COMT (catechol-O-methyltransferase) and MAO 
(monoaminoxidase) enzymes playing important roles in Alzheimer and Parkinson 
diseases by especially flavonoids, flavonoid glycosides, catechins and alkaloids are 
available (Chen et al., 2006; Kadowaki et al., 2005; Kong et al., 2004; Perry et al., 
1999). On the other hand, according to these studies, in order to accept a substance that 
can inhibit at least one of these enzymes as a new drug, the interactions of this 
compound with the other enzymes, metabolites and receptors must be elucidated. 
Therefore, the plants employed to inhibit AChE, COMT and MAO enzymes are 
summarized in Table 2.1.  
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Table 2.1. Plants of which therapeutic potentials have been investigated in the treatment of Alzheimer and Parkinson diseases. 
Family Botanical name Known name Active Ingredients Metabolic Functions Reference (s) 
Theaceae Camellia sinensis Tea (green) Catechin and catechin gallats COMT inhibition 
Chen et al., 2005         
Nagai et al., 2004    
Zhu et al., 2004  
Arecaceae Areca catechu  Areca nut palm alkaloids (pilocarpin), tannin and gallic acid AChE inhibition Houghton et al., 2005  
Piperaceae Piper betel  Betel pepper catechins and alkaloids AChE inhibition Houghton et al., 2005 
Labiateae Salvia officinalis sage Flavonoids and essential oils AChE inhibition Houghton et al., 2005 
Labiateae Melissa officinalis  melisse monoterpenes (essential oils) AChE inhibition, antidepressant Houghton et al., 2005  Wake et al., 2000  
Labiateae Salvis Lavandulaefolia Not known monoterpenes (essential oils) AChE inhibition Perry et al., 2002  
Ginkgoaceae Ginkgo biloba Ginkgo, Maidenhair Tree  
Flavonoid glycosides, 
terpenes AChE and MAO inhibition 
Sloley et al., 2000  
Perry et al., 1999     
Malpighiaceae Banisteriopsis caapi Ayahuasca, caapi alkaloids (beta carbolines) COMT and MAO inhibition Schwarz et al., 2003  
Cannabaceae Cannabis sativa cannabis Cannabinoids Cholinergic and dopaminergic activity increase Joy et al., 1999  
Cupressaceae Biota orientalis  Platycladus Not known Anticholinergic agent, MAO inhibition 
Howes et al., 2003    
Lin et al., 2003  
Liliaceae Lilium brownii  Brownii lily steroid saponines and alkaloids MAO inhibition Lin et al., 2003  
Rubiaceae Gardenia jasminoides Gardenia Glycosides and phenolic acids MAO inhibition Lin et al., 2003  
Rubiaceae Uncaria rhynchophylla  caper berry  alkaloids (indole) AChE and MAO inhibition 
Hou et al., 2005   
Mamedov, 2005  
Huperziaceae Huperzia serrata cinque foli alkaloids (huperizin A) AChE inhibition Cheng et al., 1998, 1996  Zhang et al., 1991    
                                                                                                                                                                              (continued on next page) 
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Table 2.1. (cont.) 
Family Binomial name  Known name Active ingredients Metabolic Functions Reference (s) 
Labiatae Origanum majorana Marjoram Flavonoids and essential oils AChE inhibition Chung et al., 2001  
Apiaceae Bacopa monniera   Coastal waterhyssop, Brahmi  
Alkaloids and saponins 
(bacosite) 
Learning and comprehension 
strength  
Howes et al., 2003  
Perry et al., 1999     
Solanaceae Withania somnifera  chinese lantern Steroids (witanolites) Anticholinergic agent Perry et al., 1999   Schliebs et al., 1997  
Guttiferae  Hypericum perfaratum St.John's wort 
flavonoids, tannins, 
naphtodiantrons 
(hyperphorin, hypericin) 
Memory strength, antidepressant
Mamedov, 2005 
Perry et al., 1999  
Chatterjee et al., 1998   
Zygophyllaceae Peganum harmala Harmal Alkaloids (beta carbolins) KOMT and MAO inhibition Akalın, 2003 Schliebs et al., 1997  
Rosaceae Rosa Damascena Rose Essential oils Learning and comprehension strength Köse et al., 2007  
Fabaceace Mucuna pruriens A kind of aquarium plant Not known Dopamine agonist Manyam et al., 2004 
Papaveraceae Papaver somniferum Poppy Alkaloids (papaverin, codein) AChE and COMT inhibition Perry et al., 1999  
Alliaceae Galanthus nivalis Snowdrop Alkaloids (galantamine) AChE inhibition, memory strength Olin et al., 2001a, 2001b 
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 Regarding the divergence of the plants given in Table 2.1, they serve many 
resources that can be applied for the treatment of diseases of those etiologies have not 
been entirely defined yet and seen in many people around the world such as Alzheimer 
and Parkinson diseases. It was reported that plants that are specifically rich in alkaloids, 
terpenes, flavonoids and flavonoid glycosides as active ingredients have potential 
therapeutic applications. 
However, since isolation of each of the active ingredients of plants separately, 
given in Table 2.1, requires time and money, the raw extracts of these plants and rarely 
their standards have been used in the studies. Among the plants that are active in 
inhibition of COMT enzyme, generally the Camellia sinensis (green tea) extract rich in 
catechin and catechin derivatives and the standards of the fractions has been studied in 
detail.  
Tea catechins and flavonoids found in abundant amounts in our dietaries are 
compounds having catechol ring and the structures of those used in the COMT 
inhibition are represented in Figure 2.11 (Zhu et al., 2004).   
 
 
Figure 2.11. Some polyphenolics used as COMT inhibitors.   
 
 
In the studies performed using the compounds shown in Figure 2.11, it was 
reported that the structure-activity relationship between polyphenolics and 
catecholestrogens found in human liver for their COMT catalyzed O-methylation 
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inhibition (Zhu et al., 2008; Bai et al., 2007). It was revealed that catechins containing 
galloil type D-rings (ECG and EGCG) have higher potential than quercetin which is 
known as a strong inhibitor (Chen et al., 2005; Nagai et al., 2004; Zhu et al., 2001). It 
was suggested that 4`,4``-di-O-methyl-EGKG which is a metabolite formed by 
methylation of (-)-Epilgallocatechin gallate (EGCG), which exhibits the highest 
inhibition effect in the enzyme kinetic analysis, might also be a new type of COMT 
inhibitor (Chen et al., 2005; Kadowaki et al., 2005; Weinreb et al., 2004).  
It has become a desired property that the drugs developed especially for the 
treatment of cancer and neurological diseases have multifunction. It was also known 
that Parkinson disease is a neurological disease that is caused by several mechanisms. 
Among these mechanisms, increase in oxidative stress (increase in free radical 
formation) is one of the mechanisms triggering the disease as previously mentioned 
(Cavalli et al., 2008). Consequently, the compounds administered against Parkinson 
disease should have antioxidant capacity as well as they have ability to inhibit the 
COMT enzyme. 
It was reported that due to decrease in glutathione concentration in the 
substantia nigra of the Parkinson patients, lipid peroxidation has increased (Akyol, 
2004). This substance is used as co-enzyme in the transformation reaction of peroxyl 
radicals to water molecule which is catalyzed by glutathione peroxidase enzyme 
(Akyol, 2004; Sirnonian et al., 1996). It was also known that increasing peroxyl radicals 
due to glutathione deficiency causes to loose the activity of alkaline phosphatase 
enzyme which is responsible for prevention of many proteins in the body (Bertolini et 
al., 2007). As a result of these mechanisms which are closely interrelated, destruction or 
misfolding of protein structures and increase in oxidative stress have been observed. 
Therefore, neuron deaths triggering Parkinson disease occur (Cavalli et al., 2008). 
In order to prevent these effects of the free radicals, quercetin which can inhibit 
COMT enzyme and possesses antioxidant capacity has been employed in the studies. 
Quercetin, shown as one of the synthetic inhibitors of COMT enzyme, was found to 
have higher protective effect on alkaline phosphatase activity and its structure than 
currently-used drug tolcapone. Moreover, its potential to deactivate the free radicals is 
known higher than those of most nitrocatecholic COMT inhibitors (Bertolini et al., 
2007). 
Although it was confirmed that antioxidants can prevent Parkinson disease and 
retard its progress, they increase risk of especially breast cancer due to decrease in the 
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COMT activity (Chen et al., 2006; Van Duursen et al., 2004; Esposito et al., 2002; Suk 
Yin, 2002; Chiueh et al., 2000). It was reported that transformation of catecholestrogens 
and catecholamines, due to they can not undergo the methylation reaction, to the 
quinone forms raises the cancer risk (Van Duursen et al., 2004; Suk Yin, 2002). 
 
2.2.2.1. Harmal (Peganum harmala) Seed 
 
Harmal (Peganum harmala), one of the plants listed in Table 2.1, is a plant of 
the family zygophyllaceae. In ancient times, medicine obtained from the seeds of this 
plant was used as an anthelmintic (to omit parasitic worms) and as narcotics. It was also 
used to prepare antidotes against poisoning and snake bites. Greeks and Romans used 
harmal against diarrhea. Today, in modern medicine, harmal is used as an anthelmintic 
and as a central nervous system stimulant (Akalın, 2003). Moreover, in ancient 
societies, since it has aphrodisiacal properties, it was used to increase sexual power 
(Akalın, 2003). 
Harmal seeds contain several types of alkaloids including betacarboline, 
tetrabetacarboline, quinasoline derivatives in more than 25 percent (Juma, 2005; 
Molchanov et al., 1996). The remaining part includes etheric oil, flavonoids and 
glycosides (Akalın, 2003; Sharaf et al., 1997). The seeds mostly contain betacarboline 
derivative alkaloids in 2-7 percent. Especially harmaline and harmine and other 
betacarboline derivative alkaloids such as harmalol, harmol, harman and peganin are the 
major alkaloids present in harmal seeds (Figure 2.12) (Grella et al., 1998; Ott, 1996; 
Khan, 1990). Additionally, a red dye can be extracted from the harmal seeds (Akalın, 
2003; Kartal et al., 2003).  
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Figure 2.12. Some major alkaloids found in harmal seed. 
(Source: Srivastava et al., 2001; Grella et al., 1998; Khan, 1990). 
 
 
The numerous studies using especially harmaline and harmine as well as other 
harmal alkaloids shown in Figure 2.12 have been performed. These alkaloids can 
substitute serotonin, inhibit MAO enzyme, stimulate central nervous system, have 
amplification effect on immune system as well as hallucinogenic and antioxidant effects 
(Halpern, 2004; Kartal et al., 2003).  
Moreover, peganine, which can pass through the blood-brain barrier, inhibits 
acetylcholine esterase and monoaminoxidase enzymes and thereby controls the 
acetylcholine and dopamine levels in the brain (Theodore, 1999). Although for most of 
the plants containing alkaloids, in vivo and cytotoxicity studies have not been completed 
yet, it was claimed that the alkaloids extracted from the plants in the belladonna, 
harmala and aporphine families can be utilized in the treatment at early stages of 
Parkinson disease (Theodore, 1999). 
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2.2.2.2. Olive (Olea europaea) Leaf 
 
 Olive tree, the most important member of the oleaceae family, is known as 
symbol of Mediterranean and peace since ancient times (Bonilla et al., 2006; Al-
Azzawie et al., 2006). Olive leaves, which are referred even in the Bible, have been 
used as a medicine against fever and malaria since ages (Lee-Huang et al., 2003). 
Furthermore, since it can decrease the blood pressure and prevent spasms, it has been 
used for treatment purposes in animals and humans (Garcia et al., 2000). Today, the 
clinical studies and our daily experiences have showed that olive leaf extract is effective 
against diabetes, hepatitis, flu, open wounds, bacterial and viral infections and even 
HIV (Page, 2002).  
 It was stated that the high polyphenolics content of olive leaves is responsible 
for the health beneficial and therapeutic properties of olive leaves against several 
diseases. It was reported that oleuropein and its derivatives (verbascoside); flavones 
(luteolin-7-glycoside, apigenin-7-glycoside, diosmetin-7-glycoside, luteolin and 
diosmetin); flavonoles (rutin); flavan-3-ols (catechins) and substituted phenolics 
(tyrosol, hydroxytyrosol, vanillin, vanillic acid and caffeic acid) are the most widely 
present polyphenols in olive leaves (Garcia et al., 2000). 
Among these polyphenolics, it was revealed that rutin, luteolin, hydroxytyrosol 
and oleuropein have the highest antioxidant capacities (Baycin et al., 2007; Garcia et al., 
2000). Moreover, it has been possible to isolate the major polyphenolics rutin and 
oleuropein present in olive leaves of which the chemical structures are shown in Figure 
2.13 by the silk fibroin adsorption technique (Baycin et al., 2007; Savournin et al., 
2001; Garcia et al., 2000).  
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Figure 2.13. Chemical structures of major polyphenolics in olive leaf. 
 
 
The studies on major olive leaf polyphenolics have shown that they have several 
health beneficial properties. Moreover, it was known that oleuropein has blood pressure 
and immune system regulating and therapeutic effects mainly against heart related 
diseases and diabetes as well as has antibacterial and antitumour activities. Besides, it 
was revealed that oleuropein and hydroxytyrosol which is an oleuropein derived 
metabolite have significant antioxidant capacity (Ranalli et al., 2006; Al-Azzawie et al., 
2006). 
There exists also infection preventing, antitumour, antibacterial, and antioxidant 
effects of rutin that is the secondary major polyphenolics present in olive leaves (Ghica 
et al., 2005). In addition, rutin is a compound which has been used for treatment against 
several diseases due to its preventing effect against DNA destruction and also used 
mostly in our dietaries (Kurisawa et al., 2003).  
The researches on the use of phytochemicals against neurological disorders as 
well as several diseases have still been performed (Perry et al., 1999). The importance 
of these compounds in the drug discovery and development point of view has been 
increasing due to their possible uses in several metabolic routes as substrates, protective 
and reaction initiating agents and also stabilizers (Sheu et al., 2004).  
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2.3. Enzyme Activation and Inhibition Determination Methods 
 
Most of the enzymatic reactions can be explained using equations known as 
simple Michaelis kinetics. According to Michaelis kinetics, reaction velocity (v) is 
mathematically associated with enzyme (E), substrate (S), enzyme-substrate complex 
(ES), product (P) and reaction constants (k1, k-1 and k2) as given in Equation 2.1.  
E + S          ES        E + P
k1                
k -1  
k2     
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dt
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The enzyme activity revealing the kinetic progression (Figure 2.14) of reaction 
can be followed by many physicochemical methods. Spectrophotometric, fluorometric 
and radioactive methods are referred as the most widely used techniques in the literature 
(Copeland, 2000). However, as given in the equations above, since the reaction rate can 
be calculated according to substrate and the product, it is quite important to define the 
materials of which the kinetic data will be recorded in choosing kinetic definition 
method. 
 
 
Figure 2.14. General enzymatic reaction progression curve 
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2.3.1. Spectrophotometric Method 
 
In spectrophotometric method, the changes in the electronic orientation of a 
molecule after exposure to a light source are observed. The light energy absorbed by the 
molecule and which will cause required amount of change in the electronic orientation 
of the molecule, is present in regions of electromagnetic spectrum known as ultraviolet 
(UV) and visible regions (totally 200-800 nm range) (Copeland, 2000). 
In reactions followed with spectrophotometric method, the molecule, kinetic 
data of which will be collected, should firstly be exposed to a total spectral energy 
range. Thus, the wavelength (λmax) of the maximum light energy absorbed by the 
molecule is defined and this wavelength is used for most accurate kinetic results. 
Absorption values and concentrations of materials in the solution obtained as a 
result of kinetic measurements at maximum wavelength are analytically associated 
using Beer Law (Copeland, 2000). According to Beer Law;  
clA ε=   
where A (absorbance) is a unitless quantity, and it is shown that it changes in correlation 
with concentration value defined as C (molarity, M), l (the pathlenght of light, distance 
passed by the light in the solution, cm) and ε (molar absorptivity coefficient, (M.cm)-1) 
(Copeland, 2000). 
 
2.3.2. Fluorometric Method 
 
As in spectrophotometric method, in fluorometric method the molecule is 
exposed to a light source. However, the light absorbed by the molecule in this method 
does not cause a change in electron orientation. Electrons, using the applied light 
energy, achieve high energy level for a short while and then turn to their initial energy 
level. The energy used during this change is given to reaction medium and recorded as 
increases or decreases in fluorescence (Copeland, 2000). 
In fluorometric method, 2 maximum wavelengths are defined for the molecule 
whose kinetic data will be collected. Maximum wavelengths where the light is absorbed 
(emission) and electrons reach high energy level (excitation) are found with spectral 
scanning and measurements at these wavelengths are recorded. 
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The relationship between concentration and fluorescence can be calculated with 
a method similar to Beer’s law used in spectrophotometric method. In fluorometric 
calculations, molar quantum constant (φ) is used instead of molar absorptivity. 
However, it is recommended that in practice a calibration curve is obtained for the 
material whose kinetic data will be collected instead of using this constant (Copeland, 
2000). 
Since fluorescence devices are more sensitive and less interference is observed, 
this method is more advantageous than absorption and used more for enzymatic 
reactions (Copeland, 2000). 
 
2.3.3. Radiochemical Method 
 
The basic strategy in this method is the use of radioisotopes combined with 
substrate (such as carbon-14, phosphorus-32, tritium, etc.). Such materials which are 
subject to radioactive decay pass to the product as a result of enzymatic reaction. After 
substrate and product fractions are obtained using appropriate separation techniques, 
reaction rate is determined according to the amount of radioactive material left in the 
substrate (or passed in the product) (Copeland, 2000). 
Radioactive decay is expressed with Curie unit (Ci). 1 Ci equals to complete 
decay rate of 1 gram of radium-226. After the amount of decay in one minute is defined 
for every isotopes used in the reaction, the reaction rate can be calculated (Copeland, 
2000). 
Physically, the light emerging as a result of scintillation by the radioactive 
material is absorbed by other materials in the reaction medium. The absorbed light is 
recorded by a scintillation counter. In this method which requires a separation, the 
scintillation counter is usually connected to a chromatography device. This method is 
known as a method as sensitive as fluorescence and is widely used. 
Other than these methods used for kinetic measurements of enzymatic reactions, 
some different techniques such as polarography, electrophoretic separation, 
chromatographic separation and immunological reactivity are also used (Copeland, 
2000). 
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2.3.4. COMT Enzyme Activity/Inhibition Assays 
 
It is known that the COMT enzyme, which is usually obtained by isolating from 
livers, kidneys and brains of animals and humans, can be used many catecholic 
substrates together with SAM as substrate. In studies since 1958, COMT enzyme 
activity is tried to be determined by fluorometric, spectrophotometric and radioactive 
methods. Among these, radioactive method is preferred since it does not require a 
reference standard. In this method, usually carbon-14 (14C) and tritium (3H) 
radioisotopes bound SAM is used as methyl donor substrate. However, because of 
inability to separate several isomeric O-methylated products formed in in vitro 
experiments by using liquid-liquid extraction and primitive chromatography techniques, 
radioactive methods can not always be applied (Lautala, 2000).  
With the help of improved separation methods in recent years, it is possible to 
use multiple detectors compatible with liquid and gas chromatography devices. Thus, 
spectrophotometric, fluorometric and radioactive methods with increased sensitivity 
have been used in many studies in order to determine COMT activity. However, since 
fluorometric and radioactive methods are preferred more since they have the capacity to 
measure very low concentration values (Lautala, 2000; Reenilä, 1999).  
In Table 2.2, the studies employed in order to determine enzyme activity or 
inhibition, are summarized by giving information about reaction medium, substrate 
selections and some kinetic data. As it can be seen from this table, COMT activity can 
be determined by using a variety of methods from simple optical methods to modern 
techniques. 
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Table 2.2. COMT activity/inhibition assays 
Reference(s) Assay conditions Method of Analysis 
Catecholic 
Substrate 
[Catecholic 
Substrate]  
[SAM] 
Enzyme source 
(amount) 
Additional information 
Tsunoda et al., 
2002  
pH=7.8, 37 °C,            
total rxn. volume=300 µl, 
incubation time=60 min.  
HPLC-Fluorescence 
(excitation 430 nm; 
emission 505 nm) 
Norepinephrine 
(NE) 
2 mM  200 µM 
human         
S-COMT 
[NE] concentration range 
10-2000 µM 
Tsunoda et al., 
2002  
pH=7.4, 37 °C,            
total rxn. volume=300 µl, 
incubation time=60 min. 
HPLC-Fluorescence 
(excitation 430 nm; 
emission 505 nm) 
Norepinephrine 
(NE) 
0.1 mM  200 µM 
human         
MB-COMT 
[NE] concentration range 
1-100 µM 
Salyan et al., 2006 
pH=7.5, 37 °C,            
total rxn. volume=200 µl, 
incubation time =90 min. 
LC-MS1 
1) Dopamine    
2) DOBA2 
2-128 µM     
(for both 
substrates) 
10 µM 
S-COMT       
(2 µg/ml) 
Km (DOBA) = 11 µM      
Km (Dopamine) = 42 µM 
Aoyama et al., 
2005 
pH=7.8, 37 °C,            
total rxn. volume=250 µl, 
incubation time =60 min. 
HPLC-Fluorescence 
(excitation 430 nm; 
emission 505 nm) 
Norepinephrine 
(NE) 
1.5 mM  200 µM 
S-COMT       
(62 µg/ml) 
Km (NE) = 503 µM 
(inhibition with pyrogallol 
and 3,5-dinitrocatechol ) 
Shen et al., 2005  
pH=7.8, 37 °C,            
total rxn. volume=1 ml, 
incubation time =60 min. 
HPLC-Fluorescence 
(excitation 260 nm; 
emission 400 nm) 
DOBA 25 µM 100 µM 
S-COMT       
(0.5 mg/ml) 
  
Lautala et al., 
2001, 1999  
pH=7.4, 37 °C,            
total rxn. volume=250 µl, 
incubation time =30-60 
min. 
Radioactivity-UV 
detection (260 nm) 
HPLC 
DOBA 5-300 µM 150 µM 
S-COMT       
(12.5-100 µg) 
Inhibition and Validation 
study 
                                                                                                                                                                                   (continued on next page)  
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Table 2.2. (cont.) 
Reference(s) Assay conditions Method of Analysis 
Catecholic 
Substrate 
[Catecholic 
Substrate] 
[SAM] 
Enzyme source 
(amount) 
Additional Information 
Chen et al., 2005  
pH=7.4, 37 °C,            
total rxn. volume=100 µl, 
incubation time=30 min. 
HPLC 
Electrochemical 
Detection (ECD) 
1) 2-OH-E23     
2) 4-OH-E24 
50 µM 60 µM 
Human liver 
COMT         
(0.2 mg) 
Inhibition study (substrate 
concentrations vary 
between 5-200 µM ) 
Bailey et al., 2004 
pH=7.45, 37 °C,           
total rxn. volume=60 µl, 
incubation time=60 min. 
HPLC - UV detection 
(370 nm) 
Catecholic 
Azo-dyes 0.5-150 µM  20 mM 
Porcine liver 
COMT        
(125 U/ml) 
Inhibition study (inhibitor 
concentrations vary 
between 0-21 µM ) 
Kurkela et al., 
2004   
pH=7.4, 37 °C,            
total rxn. volume=100 µl, 
incubation time=60 min. 
Microplate Reader - 
Fluorescence     
(excitation 355 nm; 
emission 460 nm) 
Esculetin Not given 10 µM 
Human liver 
COMT         
(15 µg/ml) 
Inhibition study           
(6 different catecholic 
compound) 
Veser, 1987  
pH=7.4, 37 °C,            
total rxn. volume=500 µl, 
incubation time=30 min. 
Fluorescence         
(excitation 390 nm; 
emission 465 nm) 
Esculetin 4 µM   600 µM 
Candida 
tropicalis       
S-COMT       
(20-50 µl) 
[Esculetin] = 1.2-5 µM 
[SAM] constant at 460, 46 
and 7.7 µM 
Hirano et al., 2007 
pH=7.8, 37 °C,            
total rxn. volume=200 µl, 
incubation time=30-120 
min.   
HPLC-Fluorescence 
(excitation 430 nm; 
emission 505 nm) 
Norepinephrine 
(NE) 1.5 mM   200 µM 
rat brain        
S-COMT       
Activity test for COMT 
isolated from several 
regions of rat brain 
                                                                                                                                                                                    (continued on next page)  
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Tablo 2.2. (cont.) 
Reference(s) Assay conditions Method of Analysis 
Catecholic 
Substrate 
[Catecholic 
Substrate] 
[SAM] 
Enzyme source 
(amount) 
Additional Information 
Hirano et al., 
2007  
pH=7.0, 37 °C,            
total rxn. volume=200 µl, 
incubation time=30-120 
min. 
HPLC-Fluorescence 
(excitation 430 nm; 
emission 505 nm) 
Norepinephrine 
(NE) 200 µM 200 µM 
rat brain      
MB-COMT     
Activity test for COMT 
isolated from several 
regions of rat brain 
Dhar et al., 2000  
pH=7.5, 35 °C,            
total rxn. volume=1 ml, 
incubation time=30 min. 
Spectroscopy         
(absorbance 510 nm) Esculetin 1 mM   2 mM 
Streptomyces 
griseus         
S-COMT       
(20-200 µg) 
Km (esculetin) = 500 µM    
Km (SAM) = 600 µM  
Homocystein (product) 
inhibition (Ki=224 µM)   
Zhu et al., 2001  
pH=7.4 and 10.0, 37 °C,    
total rxn. volume=1 ml, 
incubation time=20 min. 
Radioactivity-UV 
detection (254 nm) 
HPLC-MS 
Tea catechins 10-100 µM 50 µM 
Human liver  
COMT         
(0.5 mg/ml) 
Inhibition with tea 
catechins (10-100 µM) 
Palma et al., 2006 
pH=7.8, 37 °C,            
total rxn. volume=1 ml, 
incubation time=15 min. 
HPLC-EIMS5 
Nitrobenzo-
phenone 
derivatives 
(bisubstrates) 
10 µM 500 µM 
rat             
S-COMT       
(1 mg/ml) 
Inhibition with bisubstrate 
inhibitors (10 µM) 
 
 
1 LC-MS: Liquid chromatography-mass spectroscopy 
2 DOBA: 3,4-dihydroxy-benzoic acid 
3 2-OH-E2: 2-hydroxy-estradiol 
4 4-OH-E2: 4-hydroxy-estradiol 
5 HPLC-EIMS: High pressure liquid chromatography - electrospray ionization mass spectroscopy  
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2.4. Enzyme Inhibition Mechanisms 
 
 Activity of an enzyme can be blocked by various methods. It has been known 
that hundreds of natural compounds and thousands of synthetic chemicals can inhibit 
catalytic activity of enzymes. Basically these compounds cause reduction in rate of the 
enzyme catalyzed reactions (Leskovac, 2003; Copeland, 2000). Inhibition is a situation, 
which is sometimes undesirable although it is necessary for some enzymatic reactions. 
Especially, inhibition of enzymatic reactions in living organisms is widely discussed in 
food and pharmaceutical fields. 
 Inhibition is simply caused by materials which are directly or indirectly added to 
the reaction medium. These materials are called inhibitors and they are classified 
according to their effects on the reaction. The equations derived by Michaelis and 
Menten in order to calculate the rate of a simple enzymatic reaction given in Section 
2.3, are modified according to the type of the inhibitor. Despite the fact that, new rate 
equations are derived in order to explain complex mechanisms nowadays, most 
enzymatic reactions can be explained with Michaelis-Menten approach (Pekin, 1970). 
Therefore in this study, equations derived for inhibitors explained by linear inhibition 
mechanisms are used. 
 
2.4.1. Competitive Inhibitors 
 
Competitive inhibitors are usually compounds having similar structures to 
substrate of the enzyme and therefore they are bound to the same active site of enzyme 
with the substrate (Leskovac, 2003). Consequently, they reduce the production rate by 
forming an enzyme-inhibitor complex (EI) (Figure 2.15).  
 
 
 
Figure 2.15. Simple competitive inhibition                                                            
(Source: Copeland, 2000). 
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 Possible competitive inhibition reaction shown in Figure 2.15 occurs as given 
below.  
 
 
Rate of reaction for the reaction in which the medium does not include any 
inhibitors is mathematically derived as given in Equation 2.1.  
                                              [ ] [ ] [ ][ ]SK
SVv
dt
Pd
dt
Sd
m +
===− max                                        (2.1) 
In this equation [ ]0max EkV cat=  and it is defined as the maximum velocity of 
reaction. ( )
1
21
k
kkK m
+= − , which is the affinity of the substrate, is the equilibrium 
constant of the reaction where enzyme-substrate complex (ES) forms. In cases where 
there is a competitive inhibitor (I) in such reaction medium, the rate equation given in 
Equation 2.1 can be derived as in Equation 2.2 by Michaelis-Menten approach (mass 
balance is made for total E amount taking into consideration the pseudo-steady state 
hypothesis) (Shuler, 2001; Copeland, 2000).  
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 Ki, the equilibrium constant of the reaction through which the enzyme-inhibitor 
(EI) complex is formed, is defined as inhibition constant and it has the same unit with 
concentration. Using rate equations known as Michaelis-Menten equations, 
determination of inhibition mechanism and kinetic constants require complex 
calculations. For this purpose, some researchers such as Lineweaver and Burk, Hanes 
and Dixon have linearized these equations (Leskovac, 2003). Among these, linear 
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equations derived by Lineweaver and Burk are the most widely used equations in order 
to illuminate mechanism and kinetic constants graphically. 
 Linear form of competitive inhibition rate derived by the method developed by 
Lineweaver and Burk (double reciprocals of Equation 2.2) is given in Equation 2.3.  
                                                     [ ] maxmax
, 111
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K
v
appm +⎟⎟⎠
⎞⎜⎜⎝
⎛=                                          (2.3) 
where [ ] ⎟⎟⎠
⎞
⎜⎜⎝
⎛ +=
i
mappm K
IKK 1,  and when 1/[S] graph is drawn against 1/v, it can be 
calculated from the intersect points on the x-axis. Vmax value is calculated from the 
point intersecting the y axis as can be understood from the equation. A graphical 
demonstration of linear function of rate obtained for competitive inhibition and known 
as Lineweaver-Burk graph is given in Figure 2.16.  
 
 
Figure 2.16. Lineweaver-Burk graph for competitive inhibition                                 
(Source: Leskovac, 2003). 
 
 
As it can be understood from Figure 2.16, maximum velocity of an enzymatic 
reaction is not affected by the increase in inhibitor concentration in presence of 
competitive inhibitor. However, increase in inhibitor concentration increases the value 
Km,app. 
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2.4.2. Noncompetitive Inhibitors 
 
Noncompetitive inhibitors allow the binding of the enzyme to the substrate as 
given in Figure 2.17. Although these inhibitors bind to the different site of enzyme from 
the substrate, they reduce the production rate by forming solely EI or ESI complexes or 
both (Leskovac, 2003).  
 
Figure 2.17. Simple noncompetitive inhibition                                                         
(Source: Copeland, 2000). 
 
 
Possible kinetic model developed for noncompetitive inhibition is demonstrated 
below. According to this model, the equilibrium constants of the reactions, through 
which ES and ESI complexes and EI and ESI complexes are formed, are equal to each 
other. Reaction rate is derived as given in Equation 2.4, according to Michaelis-Menten 
approach.  
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Linear transformation of noncompetitive inhibition rate is also derived with the 
method developed by Lineweaver-Burk as given in Equation 2.5.  
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Lineweaver-Burk graph given in Figure 2.18 can be obtained. Required calculations can 
be applied by using the points intersecting the axes of this graph. 
 
 
Figure 2.18. Lineweaver-Burk graph for noncompetitive inhibition                                      
(Source: Leskovac, 2003). 
 
 
Increase in the concentration of a noncompetitive inhibitor, on contrary to 
competitive inhibitors, does not have any effect on Km value, while decreasing 
maximum velocity (Vmax) of the reaction. 
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2.4.3. Uncompetitive Inhibitors 
 
Uncompetitive inhibitors are bound to the appropriate active site which is lately 
formed on ES complex structure after the binding of substrate as demonstrated in Figure 
2.19. Newly formed ESI is an inactive complex and thereby it reduces the catalytic 
activity of the enzyme by preventing product formation. 
  
 
 
Figure 2.19. Simple uncompetitive inhibition                                                           
(Source: Copeland, 2000). 
 
 
Kinetic model developed for possible uncompetitive inhibition is given below. 
Equilibrium constant of the reaction where ESI complex is formed is also defined as 
inhibition constant (Ki). In rate equation derived according to Michaelis-Menten 
approach (Equation 2.6) inhibition constant is indicated with an alpha (α) constant. (α) 
constant, which also exists in rate equations of competitive and noncompetitive 
inhibition but provides simplification of equations according to the value it takes, is the 
most important mathematical parameter determining the inhibition mechanism 
(Copeland, 2000). (α) constant is used in rate equations in order to explain the affinity 
of the enzyme to the substrate with binding degree of the inhibitor.   
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According to this, for values of (α) much higher than 1, (α>>1) inhibition 
mechanism is explained as competitive, and for its values much lower than 1 (0<α<<1) 
it is explained as uncompetitive. For noncompetitive inhibition (α) constant equals to 1. 
In mixed type inhibitions where degree of competitiveness or noncompetitiveness can 
be determined, it is known that the (α) constant takes a certain lower or higher values 
close to 1 (α<1 or α>1) (Copeland, 2000).  
Linearized rate equation derived in order to explain the uncompetitive inhibition 
mechanism graphically is given in Equation 2.7.  
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Burk graph obtained in order to calculate kinetic constants given in linear rate equations 
of uncompetitive inhibition is given.  
 
 
Figure 2.20. Lineweaver-Burk graph for uncompetitive inhibition                                       
(Source: Leskovac, 2003). 
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2.4.4. Mixed Type Inhibitors (Noncompetitive and Competitive) 
 
In mixed type inhibitions which are similar to noncompetitive inhibition as 
kinetic model, affinity of inhibitor material to E and ES complex are different. (α) 
constant expressed in explaining uncompetitive inhibition can give information about 
the dominant mechanism of mixed type inhibition. In this inhibition type, whose 
reaction rate equation (Equation 2.8), (α) constant takes a certain lower or higher values 
close to 1 (α<1 or α>1). 
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Linearized rate equation, derived in order to explain this mechanism graphically 
where competitive and noncompetitive inhibitions occur simultaneously, is given in 
Equation 2.9.  
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Lineweaver-Burk graph obtained by linear rate equation of mixed type inhibition is 
given in Figure 2.21.  
  45
 
Figure 2.21. Lineweaver-Burk graph for mixed type inhibition                                           
(Source: Leskovac, 2003). 
 
 
As it can be understood from Figure 2.21, an inhibitor behavouring in mixed 
type manner affects both Km and Vmax values, however while Km increases, Vmax 
decreases. 
 
2.4.5. Inhibitor Substrates 
 
Despite there is no inhibitor in the reaction medium, a decrease in catalytic 
activity is observed. It is indicated that high substrate concentration is the main reason 
of this situation. Because the substrate can bind to both enzyme and ES complex 
simultaneously, inactive ES2 complex forms as indicated in the kinetic model below. 
Inhibition of enzyme by its substrate can again be expressed mathematically by 
Michaelis-Menten approach and the derived rate equation is given in Equation 2.10.  
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As can be understood from Equation 2.10, enzyme kinetics where substrate 
inhibition is observed can be explained mathematically by hyperbolic functions. In this 
respect, Lineweaver-Burk graph developed for determining kinetic constants in case of 
substrate inhibition is obtained through hyperbolic linearization techniques (Figure 
2.22). 
 
 
Figure 2.22. Lineweaver-Burk graph for substrate inhibition                                
(Source: Shuler, 2001). 
 
 
In order to find the kinetic constants in points intersecting the axes, from the 
hyperbolic function obtained according to the substrate concentration, a linear line 
equation which is tangent of the area belonging to the low substrate concentrations is 
derived. From the points of this tangent intersecting the axes, Vmax and Km values can be 
calculated. 
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CHAPTER 3 
 
OBJECTIVES 
 
The main aim of this study is to investigate the inhibition potentials of alkaloid 
and polyphenolic based extracts and fractions obtained especially from harmal (P. 
harmala) seeds and olive (O. europaea) leaves and also from leaves of some plants 
which are known to have high polyphenolic content like olive against COMT enzyme 
activity. In accordance to this aim, the goals of the study are listed below: 
? To extract of harmal seed alkaloids and olive leaf polyphenols by the highest 
yield methods, 
? To examine the parameters affecting extraction efficiency such as 
temperature, pH and solvent type, 
? To fractionate extracts obtained from harmal seed and olive leaf and thus to 
obtain alkaloid and polyphenolic compounds at high purity, 
? To characterize alkaloid and polyphenolic based extracts and fractions 
quantitatively and qualitatively, 
? To determine active protein amount of COMT enzyme, 
? To determine the COMT enzyme activity spectrophotometrically and 
fluorometrically and to perform inhibition studies with the most sensitive 
method, 
? To examine the inhibition potentials of eighteen alkaloid and polyphenolic 
based standards, extracts and fractions against COMT enzyme activity, 
? To compare kinetic parameters obtained as a result of inhibition study with 
values reported in literature and to report these data into the literature. 
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CHAPTER 4 
 
EXPERIMENTAL STUDY 
 
4.1. Materials 
 
The olive leaf (Olea europaea) and the other 4 plant leaves that were used in the 
inhibition studies; vitex (Vitex agnus-castus), terebinth (Pistacia terebinthus), mastic 
(Pistacia lentiscus) and cistus (Cistus parviflorus) were collected in May, 2006 from 
Izmir Institute of Technology Campus (Urla) and Karaburun region. The harmal 
(Peganum harmala) seeds were purchased from local herbalist. Analytical grade ethanol 
(C2H5OH) used in extraction of the plants other than the harmal was obtained from 
Sigma-Aldrich Chemie GmbH (Germany). HPLC-grade methanol (CH3OH), 
ammonium hydroxide (NH4OH) and chloroform (CHCl3) solvents used in the extraction 
of alkaloids present in the harmal seed were also purchased from Sigma-Aldrich 
Chemie GmbH (Germany). Petrolium ether and hydrochloric acid (HCl) used in the 
extraction of the alkaloids were taken from Riedel-de Haen (Germany) and Merck 
KGaA (Germany), respectively. Several solvents were used in the analysis of the 
exctracts obtained from the plants and their fractions by High Performance Liquid 
Chromatography (HPLC) as mobile phases. These were acetonitrile (CH3CN) that was 
purchased from Sigma-Aldrich Chemie GmbH (Germany), isopropyl alcohol (C3H7OH) 
and triethylamine (N(CH2CH3)3) that were obtained from Riedel-de Haen (Germany), 
formic acid (HCOOH) and acetic acid (CH3COOH) that were purchased from Merck 
KGaA (Germany). 
In the experiment of determination of the protein amount by Bradford method, 
Bovine Serum Albumin (BSA) which was obtained from Merck KGaA (Germany) was 
used as the reference protein. Catechol-O-methyltransferase (COMT) enzyme isolated 
from porcine liver and the substrate used as methyl source, S-adenosyl-L-methionine 
(SAM), was supplied from Sigma-Aldrich Chemie GmbH (Germany). Other reactants 
used in the fluorometric enzyme activity assays, aesculetin (6,7-dihydroxycoumarin), 
magnesium chloride (MgCl2) and L-cysteine, were also purchased from Sigma-Aldrich 
Chemie GmbH (Germany). Potassium phosphate (K2HPO4/KH2PO4) used as the buffer 
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solution was obtained from Fluka/Merck (Germany). Dimethylsulfoxide (DMSO) used 
as the solvent of the inhibitor was supplied from Carlo-Erba Reagents (Spain). The 
reactants used in the enzyme activity experiments performed by spectrophotometric 
method, dihydroxyacetophenone (substrate-DHAP), dithiothreitol (DTT), and N-
Tris(hydroxymethyl)-methyl-2-aminoethane sulphonic acid (TES) used as buffer 
solution, and boric acid were purchased from Sigma-Aldrich Chemie GmbH 
(Germany). Sodium hydroxide (NaOH) used in order to adjust the pH of the buffer 
solution was supplied from Riedel-de Haen (Germany).   
The standards used in the enzyme inhibition experiments, 3,5-dinitrocatechol 
(3,5-DNC), harmine ve harmol hydrochloride dihydrate, were purchased from Sigma-
Aldrich Chemie GmbH (Germany), and harmaline ve harmalol hydrochloride dihydrate 
from Fluka (Germany). The oleuropein and rutin standards were supplied from 
Extrasynthese (Genay, France) and Merck KGaA (Germany), respectively. 
 
4.2. Methods 
 
The methods developed and used in this study consist of six steps. In the first 
three steps, the plant extracts and their fractions that were used as inhibitors were 
obtained and characterized by using High Performance Liquid Chromatography 
(HPLC). In the other steps, protein amount and activity of the enzyme were determined 
and enzyme inhibition kinetic studies were performed using the plant extracts and their 
fractions. Two different analysis methods were applied in the activity determination and 
inhibition studies and their sensitivities were compared. The schematic representation of 
the strategy and methods followed during the study is shown in Figure 4.1. 
 
4.2.1. Extraction of the Inhibitors   
 
4.2.1.1. Extraction of Harmal (P. harmala) Seeds 
 
For the extraction of alkaloids present in the seed of harmal (P. harmala), 
different extraction methods reported in the literature were reviewed, applied in this 
study and the generally used methods including maceration, soaking and Soxhlet 
extraction were compared based on the yield. The details of the methods were given 
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below by which some parameters affecting to the extraction efficiency such as solvent 
type, temperature, extraction period and pH were investigated. 
 
 
Figure 4.1. Schematic representation of the experimental studies 
 
 
Method A (Maceration using Methanol): In this method where methanol was 
used as solvent, the effects of extraction period and pH on the extraction yield were 
studied. 
Step 1: An amount of dried and ground P. harmala seeds,  
System 1 (S1): was macerated using 50 ml methanol for 1 hour for 
each four times in a stirred jacketed heater which was kept at constant 
temperature of 50 ºC  
System 2 (S2): was macerated using methanol for 24 hours in a water 
bath at 50 oC and 150 rpm. 
Step 2: The methanol solutions obtained from these two systems were filtered. 
The methanol was removed from the filtered solutions by means of SpeedVac 
vacuum evaporator. The remaining part was filtered after being dissolved in 50 
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ml of 2% HCl. The acidic solution was subjected two times to liquid-liquid 
extraction using 20 ml of petrolium ether and the acidic part was collected using 
a separation funnel. 
Step 3: In the third step, in order to examine the effect of pH on the extraction 
yield, pH values of the solutions obtained from the two systems were increased 
by addition of ammonium hydroxide. The pH values of the final solutions are 
given below.  
System 1-1 (S1-1): pH = 10.0 
System 2-1 (S2-1): pH = 11.0 
System 2-2 (S2-2): pH = 8.5 
Step 4: Finally the three solutions obtained with different acidity were subjected 
to liquid-liquid extraction using 50 ml of chloroform for four times. The 
chloroform parts were collected by using again a separation funnel and then 
chloroform was evaporated to obtain crude alkaloid extracts. 
 
Method B (Soaking): In the extraction experiments performed according to the 
soaking method, 3 different systems were studied using 3 different solvents.  
System 1 (S1): The same procedure as in the S1-1 system of the 
Method A was also applied in all the steps in Method B except for the 
first step. In the first step methanol was soaked to dry and ground 
harmal seed in a water bath at 55 oC and 150 rpm for 30 hours. 
System 2 (S2): Firstly, in order to separate oil and relevant plant 
materials present in the harmal seeds, petrolium ether was used as first 
extraction solvent. After soaking petrolium ether to the seeds at 25 oC 
for 48 hours, filtration was applied and methanol was soaked to the 
seeds at 50 oC for 8 hours. After removal of the methanol the 
remaining solid particles were dissolved in the acidic solution as 
described in the Method A, S1-1 and pH of the solution was adjusted to 
10.0 using basic solution. After that it was subjected to liquid-liquid 
extraction using chloroform. 
System 3 (S3): In this system, ethyl acetate was used as the extraction 
solvent. After being mixed with some sodium bicarbonate, it was 
soaked twice to harmal seeds at 25 oC for 24 hours. After the each 24-
hour soaking period, the basic ethyl acetate parts were collected by 
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filtration and they were subjected to liquid-liquid extraction using 25 
ml of %5 HCl. The pH of the solution after the acidic portion was 
removed by means of a separation funnel was adjusted to 3.5 by 
addition of some 5M of NaOH solution.  
 
Method C (Soxhlet Extraction): Methanol was used as solvent in this method 
in which Soxhlet apparatus was used. The effect of the extraction period on the 
extraction yield was examined. For this purpose, some ground harmal seeds were 
extracted at 70 oC for 
System 1 (S1): 7.5 hours  
System 2 (S2): 20 hours 
System 3 (S3): 26 hours. 
After that, the steps given in Method A were followed. In this method, the pH of 
the solution was adjusted to 10.0 before the extraction with chloroform. 
The results obtained from different methods applied for the extraction of 
alkaloids in the harmal (P. harmala) seeds were compared with each other. The extracts 
obtained by the method which provided the optimum yield were stored in dark glass 
bottles in a cool environment.   
 
4.2.1.2. Extraction of Olive (O. europaea) Leaves 
 
The extracts from the leaves of olive and of other plants (vitex, cistus, terebinth 
and mastic) were obtained by the same manner as reported in the literature (Altıok et al., 
2008; Baycin et al., 2007). First, the washed and dried leaves were ground and then 
subjected to extraction with % 70 aqueous ethanol solution. The extraction process was 
carried out in a thermoshaker at 25 oC and 250 rpm for 2 hours keeping solid/liquid 
ratio at 1/20. The extract obtained in the 70% aqueous ethanol solution after filtration 
was subjected to rotary vacuum evaporator in order to remove the ethanol. The extract 
in the remaining aqueous solution was dried in a freeze drier (Telstar Cryodos) of which 
the operational conditions were kept at –52 oC and at a lower pressure than 0.2 mbar. As 
a result of freeze drying, the crude extract was obtained and kept in dark glass bottles in 
a cool environment for further use in the enzyme inhibition experiments.  
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4.2.2. Fractionation of the Extracts  
 
Different fractionation techniques were applied for each of the extracts rich in 
alkaloids and polyphenolics that were obtained by the optimized extraction methods. 
 
4.2.2.1. Fractionation of the Harmal (P. harmala) Seed Extract 
 
The raw extract of the harmal seed was fractionated by use of a fraction collector 
unit (Gilson) compatible with the High Performance Liquid Chromatograph (HPLC) 
(Agilent 1100 series). The operating conditions and properties of HPLC used for 
alkaloid fractionation are given in Table 4.1.  
 
Table 4.1. The operating conditions and properties of HPLC (Alkaloid Fractionation) 
Units and Parameters Properties and Conditions 
Column Zorbax SB-C18 semipreparative column 
Column length  25 cm 
Column diameter 9.4 mm 
Particle size 5 µm 
Mobile phase A: Acetonitrile/isopropyl alcohol (1:1) (by volume) 
Mobile phase(s) 
Mobile phase B: Acetonitrile/isopropyl alcohol/Deionized 
water/Formic acid (100:100:300:0.3) (ml) (pH of the solution  was 
adjusted to 8.6 by addition of triethylamine) 
Flow rate 1 ml/min 
Temperature 30 °C 
Pressure  60-70 bar 
Detector type Diode Array Detector (DAD) 
Wavelength 330 nm 
 
 
The optimum elution program for the alkaloid fractionation was determined by 
changing the polarities of the mobile phases. The changes in the concentration of the 
mobile phases during analysis are given in Table 4.2. 
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Table 4.2. HPLC elution program (Alkaloid Fractionation) 
Time (min) Mobile Phase A (%)  Mobile Phase B (%) 
0 5 95 
18 5 95 
21 30 70 
24 38 62 
27 36 64 
30 35 65 
35 0 100 
40 0 100 
 
 
According to the results of the HPLC analysis performed for the crude alkaloid 
extract, the harmal seed alkaloids were collected in 3 fractions. These fractions collected 
being dissolved in the mobile phase, were obtained as their powder forms after removal 
of solvents by using vacuum evaporator. The powdered alkaloid fractions in were stored 
under appropriate condition until further use in HPLC characterization and enzyme 
inhibition experiments. 
 
4.2.2.2. Fractionation of the Olive (O. europaea) Leaf Extract 
 
The polyphenolics in olive leaf were fractionated using silk fibroin packed 
column as previously reported in literature (Baycin et al., 2007). Firstly, the column 
packed with 15 g of silk fibroin was eluted by deionized water, ethanol and again 
deionized water, respectively in order to remove the impurities on the packed material 
and to activate it. Then 20 g of the crude extract dissolved in 250 ml water was fed to 
the column until saturation. In order to firstly fractionate the water-soluble 
polyphenolics having high polarity such as oleuropein, the column was eluted with 
water for 9 times. The 9 water fractions were then combined into 4 main fractions based 
on their compositions determined by the HPLC analysis.  
After that, in order to fractionate the less polar polyphenolics such as rutin and 
other glycosides, the column was eluted with % 70 aqueous ethanol solution for 4 times. 
The fractions obtained were also combined into 2 main fractions according to the HPLC 
analysis results. The fractions rich in oleuropein and rutin were lyophilized and stored 
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in appropriate conditions for further use in the enzyme inhibition and HPLC 
characterization experiments. 
 
4.2.3. Characterization of the Inhibitors 
 
The plant extracts and their fractions obtained for investigation of their enzyme 
inhibition potentials were first characterized by HPLC.  
 
4.2.3.1. Characterization of the Harmal (P. harmala) Seed Extract 
 
Qualitative and quantitative characterization study of the crude harmal seed 
extract and their fractions were performed by HPLC. The obtained samples were 
filtered through 0.45 µm membrane filters prior to the analysis. The properties of the 
HPLC system and the operating conditions for analysis proper for the characterization 
of the alkaloids are given in Table 4.3.  
 
Table 4.3. Operating conditions and properties of the HPLC (Alkaloid Characterization) 
Units and Parameters Property and Conditions 
Column LiChrospher 100 RP-18 analytical column 
Column length 25 cm 
Column diameter 4 mm 
Particle size 5 µm 
Mobil phase A: Acetonitrile/isopropyl alcohol (1:1) (by volume) 
Mobile phase(s) 
Mobile pahse B: Acetonitrile/isopropyl alcohol/Deionized 
water/Formic acid (100:100:300:0.3) (ml) (pH of the solution was 
adjusted to 8.6 by addition of triethylamine) 
Flow rate 1 ml/min 
Temperature 30 °C 
Pressure 170-180 bar 
Detector type Diode Array Detector (DAD) 
Wavelength 330 nm 
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The elution program by which the optimum separation in the fractionation was 
yielded was determined by changing the polarities of the mobile phases. The changes in 
the concentrations of the mobile phases are given in Table 4.4.  
 
Table 4.4. HPLC elution program (Alkaloid Characterization) 
Time (min) Mobile Phase A (%)  Mobile Phase B (%) 
0 10 90 
3 10 90 
6 15 85 
15 15 85 
18 18 82 
20 0 100 
 
 
The measurement wavelength of 330 nm applied in both fractionation and 
characterization of the alkaloids was chosen based on the spectrophotometric scanning 
of the crude extract, its fractions and alkaloid standards performed by using microplate 
reader (Multiskan, Thermo). Furthermore, calibration curves for each alkaloid standard 
were obtained, and detection and quantification limits for the each standard were 
determined as a result of the HPLC analysis (Appendix A. Calibration Curves of 
Alkaloids and Sample Calculation). 
 
4.2.3.2. Characterization of the Olive (O. europaea) Leaf Extract 
 
Characterization of the polyphenolics in the olive leaf extract such as oleuropein 
and rutin was also carried out by HPLC in a manner reported in the literature (Altıok et 
al., 2008; Baycin et al., 2007). The properties of the HPLC system and the operating 
conditions of analysis proper for the characterization of the polyphenolics are given in 
Table 4.5.  
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Table 4.5.Operating conditions and properties of HPLC (Polyphenolic Characterization) 
Units and Parameters Property and Conditions 
Column LiChrospher 100 RP-18 analytical column 
Column length 25 cm 
Column diameter 4 mm 
Particle size 5 µm 
Mobile phase A: % 2.5 aqueous acetic acid solution 
Mobile phase(s) 
Mobile phase B: Acetonitrile 
Flow rate 1 ml/min 
Temperature 30 °C 
Pressure 120-130 bar 
Detector type Diode Array Detector (DAD) 
Wavelength 280 nm 
 
 
In order to characterize the polyphenolics present in the olive leaf extracts, the 
optimum elution program for HPLC analysis which was reported in the literature was 
given in Table 4.6. 
 
Table 4.6. HPLC elution program (Polyphenolic Characterization) 
Time (min) Mobile Phase A (%)  Mobile Phase B (%) 
0 95 5 
20 75 25 
40 50 50 
50 20 80 
60 5 95 
 
 
The concentrations of oleuropein and rutin, which are the major polyphenolics 
present in olive leaf extract which is composed of several polyphenolics, were 
determined based on the calibration curves prepared using their standards (Appendix B. 
Calibration Curves of Oleuropein and Rutin and Sample Calculation). 
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4.2.4. Determination of Protein Amount  
 
It is important to determine the amount of active protein for accurate kinetic 
calculations of an enzymatic reaction. Among the several methods reported in the 
literature for protein analysis, Bradford method was preferred in this study due to its 
high sensitivity (Rosenberg, 1996). The main principle of the Bradford method is the 
measurement of change in the absorbance value of the protein solution resulted from 
addition of an acidic dye which tends to bind to basic and aromatic amino acids into the 
solutions with different protein concentrations. In this method, calibration curves for 
both reference and sample proteins are prepared using the absorbance values obtained 
from different protein concentrations (Pierce Biotechnology Inc., 2009). 
Based on this principle, in the analysis of the active protein of the standard 
COMT enzyme isolated from porcine liver by the Bradford method, Bovine Serum 
Albumin (BSA) was used as the reference protein and Commassie Blue was used as the 
acidic dye. The stock solutions of COMT and BSA proteins in 1 mg/ml concentration 
were prepared. The calibration curves for the each protein were prepared based on the 
spectrophotometric measurements at the optimum wavelength for the 5 different 
concentrations prepared in the range of 0-16 μg/ml. In accordance with the results of the 
spectral scanning performed in wavelength range of 400-700 nm by using a microplate 
reader (Multiskan, Thermo), the optimum wavelength was determined as 595 nm. 
The active protein amount of COMT enzyme was estimated from the ratio of the 
slopes of the calibration curves prepared for both BSA and COMT.  
 
4.2.5. Determination of Enzyme Activity of COMT and Inhibition 
Kinetics  
 
The enzyme activity of COMT was determined spectrophotometrically and 
fluorometrically according to the protocols given in the literature. The inhibition 
experiments were performed by the fluorometric method which is more sensitive, less 
time consuming and more cost effective. 
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4.2.5.1. COMT Activity Determination by Spectrophotometric Method 
 
In order to determine the activity of COMT spectrophotometrically, the protocol 
prepared by Sigma-Aldrich Chemie GmbH was applied. According to this protocol, the 
absorbance values of the O-methylated products of DHAP formed as a result of the 
possible COMT catalyzed methylation reaction given below were measured at 344 nm 
by using a spectrophotometer (Multiskan, Thermo). 
 
DHAP + SAM ⎯⎯ →⎯COMT  SAH + 3H4MAP + 4H3MAP 
 
According to this protocol which was prepared on the basis of stop rate 
determination method, the reaction was carried out at 37 °C and at the pH value of 7.6. 
Total reaction volume was kept constant at 1 ml. While concentrations of methyl donor 
substrate of reaction, SAM were varied between 4-0.2 mM (serially dilutions were 
made 5, 10, 15 and 20 times), the concentration of the methyl acceptor substrate, DHAP 
was kept constant at 0.5 mM. The 150 U of COMT standard enzyme (contains 1.9 mg 
solid) was prepared in TES buffer solution having concentration of 2.55 mg solid/ml. In 
Table 4.7, the order and amount of reactants added to the reaction medium were given.  
 
Table 4.7. Reaction medium for spectrophotometric method 
Reactants Test solution (µl)  Blank solution  (µl) 
TES1 200 300 
DHAP 100 100 
SAM 100 - 
COMT 100 100 
Sodium Borate2 500 500 
 
 
 The enzyme activities were calculated using the mathematical equation given in 
the applied protocol and the results obtained for this method were given in Results and 
Discussion section of the study.  
 
1 0.2 M TES (buffer solution used in enzyme dilutions) contains 6 mM MgCl2 and 20 mM DTT. The pH 
was adjusted to 7.6 using 1 M of NaOH.   
 
2 0.4 M Sodium borate (stop solution) was prepared by adjusting the pH of boric acid solution to 10.0 
using 1 M of NaOH. 
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4.2.5.2. COMT Activity and Inhibition Kinetics Determination by 
Fluorometric Method  
 
 In determining COMT activity fluorometrically, some studies employed by 
almost the same manner were taken as basis (Kurkela et al., 2004; Veser, 1987). In this 
method, Aesculetin (ES) was used as the methyl acceptor substrate of possible COMT 
catalyzed methylation reaction given below. The transformation rate of ES to scopoletin 
was measured fluorometrically at 355 nm excitation and 460 nm emission wavelengths 
by using microplate reader (Varioskan, Thermo) for totally 2 hours during which the 
fluorescences were recorded at every 30 seconds time intervals.  
 
ES + SAM ⎯⎯ →⎯COMT  SAH + Scopoletin 
 
The two fluorescence values measured at the first 30 min. time interval of the 
steady state phase of reaction were used in kinetic calculations. One unit increment in 
fluorescence was related to the produced scopoletin concentration by using the 
calibration curve prepared with the scopoletin standard (Appendix C).  
In activity determination and inhibition studies, the total volume of reactions, 
which were carried out at 37°C and pH of 7.4, were 200 µl and 250 µl, respectively. 
Potassium phosphate solution was prepared at a concentration of 100 mM containing 5 
mM MgCl2 and 20 mM L-cystein was used as buffer solution in fluorometric method. 
In the fluorometric analysis, first the linear working concentrations were determined for 
both enzyme and substrates. As a result of this experiment, the optimum concentrations 
of enzyme and ES were found as 11 µg protein/ml and 4 µM, respectively and the 
concentrations of enzyme and ES in inhibition study were kept constant at these 
optimum values. SAM concentrations were varied between 10-600 µM throughout the 
study.  
The required concentrations for plant extracts, fractions and their standards that 
were used in inhibition study were determined for each of them. Thus, the 3,5-DNC was 
prepared in the concentration range of 0.1-0.005 µg/ml, while the concentration of other 
inhibitors were varied between 0.5-10 µg/ml. In Table 4.8, the amounts of reactants 
added to reaction medium were given for both activity determination and inhibition 
studies.  
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Table 4.8. Reaction medium for fluorometric method  
Reactants 
Test solution 
(µl) 
Blank solution 
(µl) 
Test solution 
(µl) 
Blank solution 
(µl) 
SAM 50 - 50 - 
ES 75 75 125 125 
COMT 50 50 50 50 
Buffer 25 75 - 50 
Inhibitor(s) - - 25 25 
 
 
4.2.6. Analysis of Enzyme Activity and Inhibition Kinetics Data 
 
The reaction velocity data obtained from the results of studies employed for 
determination of activity and inhibition kinetics were analyzed on the basis of the 
knowledge given in Section 2.3 and 2.4. In data analysis, a nonlinear regression 
program known as GraphPad Prism 5.0, in which the same enzyme kinetic model 
equations with those of given in Section 2.4 referring also the same kinetic models 
reported in Copeland, 2000’s book, were used. The obtained kinetic velocity data were 
analyzed by fitting them to the appropriate kinetic models which were previously given 
as Equation 2.1, 2.2, 2.4, 2.6 and 2.8. Thus, the kinetic parameters for activity and 
inhibition could be calculated. In order to test the convenience of the chosen model, 
Lineweaver-Burk graphs were also drawn for each kinetic data set. Moreover, the 
goodness of fit of the model was statistically analyzed by applying analysis of variance 
(ANOVA) to the data set which was fallowed by the Tukey’s multiple comparison tests.   
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CHAPTER 5 
 
RESULTS AND DISCUSSION 
 
Results of extraction, fractionation, characterization and enzyme 
activity/inhibition determination experiments performed by methods explained in detail 
in Chapter 4 are given in this section respectively. 
 
5.1. Obtaining and Characterization of Extracts  
 
5.1.1. Extraction of Harmal (P. harmala) Seed and its Characterization 
 
In order to obtain the alkaloids in harmal (P. harmala) seeds various methods 
whose details are given in methods section had been tried. According to this, results 
obtained from studies with maceration, soaking and Soxhlet extractions were compared 
with respect to their efficiencies.  
It is known that harmal seed dominantly consists of harmine, harmaline, harmol 
and harmalol alkaloids. In this respect, extracts obtained using different extraction 
methods were initially characterized by using High Performance Liquid 
Chromatography (HPLC). For the characterization, firstly calibration curves are 
obtained for each alkaloid standards (Appendix A. Calibration Curves of Alkaloids and 
Sample Calculation). According to this, amounts of major alkaloids present in crude 
extracts obtained with each extraction method were calculated. Extraction conditions of 
methods, in performing which some parameters such as solvent type, temperature, 
extraction time and pH were changed, were summarized in Table 5.1.  
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Table 5.1. Operation conditions for alkaloid extraction methods 
Extraction Method Solvent Type 
Temperature 
(°C) 
pH 
Extraction 
Time (hours) 
Method A*, S1-1 Methanol 50 10.0   4 
Method A, S2-1 Methanol 50 11.0   4 
Method A, S2-2 Methanol 50   8.5   4 
Method B*, S1 Methanol 55 10.0 30 
Method B, S2 
Petrolium Ether 
/Methanol 50 10.0 56 
Method B, S3 Ethyl Acetate 25   3.4 48 
Method C*, S1 Methanol 70 10.0     7.5 
Method C, S2 Methanol 70 10.0 20 
Method C, S3 Methanol 70 10.0 26 
* Method A: maceration, Method B: Solvent soaking, Method C: Soxhlet 
 
 
The alkaloid contents and efficiencies of extracts obtained with methods given in 
Table 5.1 were calculated using calibration curves obtained for alkaloid standards were 
given in Table 5.2.   
 
Table 5.2. Alkaloid contents and efficiencies of crude extracts obtained from harmal 
seed 
Extraction 
Method 
Harmol 
(mg) 
Harmaline 
(mg) 
Harmine 
(mg) 
Total amount 
of extract 
(mg) 
Initial seed 
amount (mg) 
efficiency (%) =   
(mg alkaloid*100/  
mg seed) 
Meth. A, S1-1 14.85 61.48 38.72 115.05 2000 5.75
Meth. A, S2-1 - 53.45 35.43 88.88 1550 5.73
Meth. A, S2-2 - 43.82 26.95 70.77 1550 4.57
Meth. B, S1 8.88 77.01 52.27 138.16 2000 6.91
Meth. B, S2 - 44.47 28.07 72.54 9770 0.74
Meth. B, S3 - 23.03 11.63 34.66 3100 1.12
Meth. C, S1 - 97.06 68.70 165.76 2500 6.63
Meth. C, S2 - 126.57 86.50 213.07 3500 6.09
Meth. C, S3 18.30 81.85 55.52 155.68 3500 4.45
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It is known according to the literature that harmal seed includes 2-7% of alkaloid 
(Ott, 1996). When this percentage is taken into consideration, most of the extraction 
methods given in Table 5.2 had been found adequate with respect to efficiency. Among 
the extraction parameters, effect of pH on efficiency was analyzed in Method A. 
Therefore, as it can be understood from Tables 5.1 and 5.2, extraction efficiency was 
increased when the solution pH value was 10.0 or higher. Consequently, the optimum 
pH value was determined as 10.0.  
According to the results obtained for Method B developed in order to observe 
the effect of solvent type, it was indicated that methanol was the most appropriate 
solvent for alkaloid extraction. Moreover, the highest efficiency was obtained with the 
S1 system of Method B in which methanol was used as solvent among the others. 
Soxhlet apparatus (Method C) was used in order to analyze the effect of 
extraction time on efficiency. It was found that as time passed more than one day 
period, efficiencies of extracts decreased. As it can be seen from Tables 5.1 and 5.2, 
efficiency values obtained with Method C-S1 and Method B-S1 were found very close 
to each other.  
Since, by applying Method C-S1, the required amount of efficiency could be 
achieved in a shorter time among these two methods, so it was defined as the optimum 
alkaloid extraction method. Sample chromatograms of crude alkaloid extract obtained 
using optimum alkaloid extraction method and of the mixture of standards prepared in 
order to characterize each alkaloids present in crude extract were given in Figure 5.1 
and 5.2, respectively.  
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Figure 5.1. Sample chromatogram of the crude alkaloid extract (1) harmol, (2) harmalol, 
(3) harmine, (4) harmaline (analytical column) 
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Figure 5.2. Sample chromatogram of the mixture of alkaloid standards (1) harmol,      
(2) harmalol, (3) harmine, (4) harmaline (analytical column) 
 
 
According to HPLC chromatogram obtained for the mixture of alkaloid 
standards in Figure 5.2, retention times of alkaloids in non-polar column were 
determined respectively as 3.8 min. for Harmol, 4.3 min. for Harmalol, 7.3 and 9.4 min. 
for Harmine and Harmaline. Therefore, alkaloids in harmal seed extract were 
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characterized according to their retention times (Figure 5.1). Accordingly, elusion with 
highly polar mobile phases caused high polarity alkaloids to leave the column in a 
shorter time.  
It was also observed from the HPLC analysis of crude alkaloid extracts and 
alkaloid standards mixture of which the obtained chromatograms given in Figure 5.1 
and 5.2, a shift occurred in retention times of alkaloids in crude extract. It was thought 
that the shift in the retention times may be caused by other compounds obtained from 
plant material during extraction process, their amounts and intermolecular interaction. 
As it can be observed from the sample chromatogram (Figure 5.1) given for the 
crude extract, harmine and harmaline were dominantly present alkaloids in harmal seed 
and their amounts were given in Table 5.2. Besides, harmol and harmalol content of the 
extract obtained by the Soxhlet method was found below the detection limits 
determined by their corresponding alkaloid standards, therefore amounts of them could 
not be calculated. Detection and quantification limits of standard alkaloids determined 
by their calibration concentrations were given in bold characters in Table 5.3.  
 
Table 5.3. Concentration ranges of alkaloids used for calibration 
Alkaloid Type Harmol (1) Harmalol (2)  Harmine (3) Harmaline (4) 
1050 1270 983 1180
525 635 492 590
210 254 196 236
105 127 98 118
C
on
ce
nt
ra
tio
n 
ra
ng
e 
(µ
g/
m
l) 
42 51 39 47
 
 
Moreover, an unidentified peak other than those of the four main alkaloids was 
observed and could be seen on the chromatogram of crude extract given in Figure 5.1. It 
was thought that this peak marked as (*) may be a derivative of harmol or harmalol 
alkaloids. However, it had not been characterized since it was not as dominant as the 
main alkaloids in the crude extract.  
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5.1.2. Extraction of Olive (O. europaea) Leaf and its Characterization 
 
As given in the methods section, extraction process for obtaining olive leaf 
polyphenolics was performed according to the optimum conditions in the literature 
(Altiok et al., 2008; Baycin et al., 2007). Accordingly, the powdered olive leaves 
obtained after some pretreatment processes were extracted in 70 % aqueous ethanol 
solution for 2 hours at 250 rpm and 30 °C, solid/liquid ratio was 1/20 for the extraction 
of polyphenolics.  
The obtained crude extract of polyphenolics were characterized by using HPLC 
as well as it was performed for the alkaloids and it was found that olive leaf extract 
were rich in oleuropein and rutin. Quantifications of these two main polyphenolics in 
the extract were determined by calibration of their corresponding standards. Calibration 
curves obtained for oleuropein and rutin standards were given in Appendix B with 
sample calculations. Sample chromatogram of the crude extract obtained from olive leaf 
was demonstrated in Figure 5.3.  
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Figure 5.3. Sample chromatogram of crude olive leaf extract (1) rutin, (2) oleuropein 
(Mobile phase flow rate: 1 ml/min, column temperature 30 °C, analytical 
column) 
 
 
 
  68
As it can be seen from the chromatogram, it was found that oleuropein was the 
most dominant polyphenol present in the olive leaf extract. Based on the polarities of 
polyphenolics, it was observed that rutin was more polar than oleuropein and retention 
times of both on the column were determined as 17.5 and 21.6 minutes. Other peaks 
which were not quantitatively dominant were characterized as glycosides and glycoside 
derivative polyphenolics such as luteolin-7-glycoside, verbascoside, apigenin-7-
glycoside and luteolin in the study of Altiok et al., 2008.  
Moreover, according to calibration curves obtained for oleuropein and rutin 
standards, their amounts in the crude olive leaf extract were found as 9.0% and 0.9%, 
respectively.  
 
5.2. Fractionation and Characterization of Extracts  
 
The fractionation techniques applied for extracts rich in alkaloids and 
polyphenolics which were extracted at optimum conditions were given in detail in 
methods section. 
 
5.2.1. Fractionation and Characterization of Harmal Seed Extract 
 
Harmal seed alkaloids obtained with Soxhlet extraction method (70 °C, 7.5 
hours) were collected as three different fractions by using HPLC compatible fractioning 
apparatus as given in the methods section. Fractions were characterized also by using 
HPLC-analytical column. In Figure 5.4, the chromatogram of the crude harmal seed 
extract performed in HPLC-semipreparative column conditions was given.  
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Figure 5.4. Sample chromatogram of crude harmal seed extract before fractioning       
(1) harmol, (2) harmalol, (3) harmine, (4) harmaline (Mobile phase flow 
rate: 1 ml/min, column temperature 30 °C, semipreparative column) 
 
 
According to the HPLC analysis of crude alkaloid extract with semipreparative 
column, retention times of alkaloids were found 15.6 min. for harmol, 16.2 min. for 
harmalol and 21.6 min. and 28.3 min. for harmine and harmaline, respectively. Crude 
extract was separated into 3 parts according to the retention times and their majorities in 
the extract during fractioning. As shown on the chromatogram given in Figure 5.4, 
while 1st and 2nd alkaloids detected between 14th and 18th minutes were determined as 
the first P. harmala fraction (FP 1), harmine fraction (FP 2) was collected between 20th 
and 24th minutes. Harmaline fraction (FP 3) was obtained by collecting between 27th 
and 31st minutes. 
The quantifications of the compounds in each fraction were determined 
according to calibration curves obtained for alkaloid standards after being analyzed 
them by using HPLC-analytical column. In Figure 5.5 and 5.6, chromatograms of 
harmine and harmaline fractions obtained as a result of HPLC analytical column 
analyses were given, respectively.  
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Figure 5.5. Sample chromatogram of harmine fraction (FP 2) (3) harmine, (4) harmaline      
(Mobile phase flow rate: 1 ml/min, column temperature 30 °C, analytical 
column)  
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Figure 5.6. Sample chromatogram of harmaline fraction (4) harmaline (Mobile phase 
flow rate: 1 ml/min, column temperature 30 °C, analytical column) 
 
 
As it can be seen from the chromatograms of fractions, after fractioning there 
was a shift in retention times of the 3rd and 4th alkaloids which were determined as 
harmine and harmaline alkaloids by the crude extract analysis (Figure 5.1). According 
to this, retention time of harmine peak was delayed to 8.3 minutes from 7.3 minutes, 
and retention time of harmaline peak shifted to 14 minutes from 10.5 minutes. This 
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result indicated that the polarities of fractions, of which the purities had been attempted 
to increase, decreased after fractioning.  
Purities of the fractions obtained for the major alkaloids of crude extract were 
calculated using the calibrations of the standards and the results were given in Table 
5.4. 
 
Table 5.4.Characterization results of major alkaloid fractions obtained from harmal seed 
Fraction No. Peak Percentage of Fractions (%) 
Alkaloid Name 
FP 2 FP 3 FP 2 FP 3 
Harmine peak yes traces 77.0 6.1
Harmaline peak yes yes 22.5 93.2
 
 
Other than these, HPLC analyses of FP 1 where harmol and harmalol alkaloids 
were dominant were also performed. However, according to the results, traces of many 
peaks which were thought to be derivatives of harmala alkaloids were observed. Each 
alkaloid fraction was collected, dried and stored in appropriate conditions in adequate 
amounts in order to further use in enzyme inhibition experiments.  
 
5.2.2. Fractionation and Characterization of Olive Leaf Extract 
 
Extraction, characterization and fractionation of polyphenolics in olive leaf were 
performed based on the studies of Altıok et al., 2008 and Baycin et al., 2007 as it was 
explained in detail in methods section. As can be seen from the chromatogram of crude 
extract (Figure 5.3), oleuropein and rutin polyphenols were found as dominant in olive 
leaf. Other than these, many glycoside derivatives in the crude extract were 
characterized in the study of Altıok et al., 2008. In the fractioning process performed 
using silk fibroin packed column, 6 fractions were collected whose elution solvents 
were given in Table 5.5. 
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Table 5.5. Elution solvents and contents of fractions obtained from olive leaf extract 
Fraction No. Elution Solvents and Contents 
FO 1 1st and 2nd water fraction 
FO 2 3rd and 4th water fraction 
FO 3 5th and 6th water fraction 
FO 4 7th, 8th and 9th water fraction 
FO 5 1st and 2nd 70%  aqueous ethanol fraction 
FO 6 3rd and 4th 70%  aqueous ethanol fraction 
 
 
Chromatograms of olive leaf fractions were given from Figure 5.7 to 5.12 with 
respect to their order given in Table 5.5. As a results of HPLC analysis of fractions 
which can also be understood from following chromatograms, it was found that water 
fractions were characterized as rich in oleuropein, and aqueous ethanol fractions were 
found rich in rutin and glycosides. 
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Figure 5.7. Chromatogram of olive leaf fraction coded as FO 1 
 
  
The purity of oleuropein of which the retention time was 21.6 minutes, was 
calculated as 91.0 % in the first 2 water fractions (FO 1).  
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Figure 5.8. Chromatogram of olive leaf fraction coded as FO 2 (1) rutin, (2) 
verbascoside, (3) oleuropein 
 
 
As a result of further elution the silk fibroin column with water, oleuropein 
percentage of olive leaf fraction was reduced while less amounts of polyphenolics such 
as rutin and verbascoside were observed.  
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Figure 5.9. Chromatogram of olive leaf fraction coded as FO 3 (1) rutin, (2) luteolin-7-
glycoside, (3) verbascoside, (4) oleuropein 
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Figure 5.10. Chromatogram of olive leaf fraction coded as FO 4 (1) rutin, (2) luteolin-7-
glycoside, (3) verbascoside, (4) oleuropein 
 
 
As it can be seen from the chromatograms of the water fractions given in Figure 
5.9 and 5.10, further water elution reduced the oleuropein content in the fractions to 
nearly 25%. Moreover, it was observed that the fractions obtained with aqueous ethanol 
elution, of which the chromatograms were given in Figure 5.11 and 5.12, were found 
rich in rutin and glycosides. 
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Figure 5.11. Chromatogram of olive leaf fraction coded as FO 5 (1) rutin, (2) 
verbascoside 
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Figure 5.12. Chromatogram of olive leaf fraction coded as FO 6 (other forms of 
glycosides with low polarity) 
 
 
 It was found that oleuropein contents of fraction coded as FO 5 and FO 6 
obtained with aqueous ethanol elution were below detection limits even it was not 
observed. Despite this, as it can be seen from the chromatograms, fraction coded as FO 
5 and FO 6 were characterized as fractions rich in rutin and glycosides. As a result of 
fractioning of olive leaf extract, oleuropein contents of fractions were calculated as 
percentage according to calibration curves and the results were summarized in Table 
5.6. 
 
Table 5.6. Oleuropein contents of olive leaf fractions 
Fraction No. Time (min.) Peak Intensity (%) 
FO 1 21.8 90.95 
FO 2 22.0 78.15 
FO 3 22.1 54.70 
FO 4 22.2 26.86 
FO 5 No oleuropein peak - 
FO 6 No oleuropein peak - 
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Accordingly, the purity of oleuropein, the most dominant polyphenol present in 
the olive leaf extract, could be increased up to 90% by using silk fibroin packed column 
adsorption process. Fractioning efficiency in terms of oleuropein was decreased as long 
as water elution was continued. When aqueous ethanol was used as elution solvent, 
fractions rich in rutin and glycosides which were adsorbed by the column tighter were 
obtained. Among all of the obtained fractions from olive leaf extract, fractions rich in 
oleuropein and rutin coded as FO 1 and FO 5 were obtained in adequate quantity to 
further use in enzyme inhibition studies and stored in appropriate conditions.  
 
5.3. Determination of Protein Amount 
 
As mentioned before, in the enzyme protein amount determination method 
known as Bradford method, Bovine Serum Albumin (BSA) was used as reference 
protein and Commassie blue as acidic dye. Results of the spectral scanning obtained in 
order to observe the effect of the increase in protein concentration on absorbance and to 
determine the optimum wavelength were given in Figure 5.13. As a result of this 
scanning, maximum absorbance of unbound Commassie blue (blank) to the protein was 
found as 465 nm wavelength as given in the literature (Rosenberg, 1996). By adding 
same amount of different concentrations of BSA to the blank solutions, maximum 
absorbance value shifted to 595nm from 465 nm.  
At the same time, while the increase in the protein concentration affected 
absorbances inversely between 400-525 nm, it caused an increase in the absorbance 
values between 525-700 nm. This result which is known characteristics of Bradford 
method was found in good accordance with the literature (Rosenberg, 1996). 
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Figure 5.13. Spectral scanning for different BSA concentration 
 
 
Spectrophotometric measurements were performed at 595 nm which was found 
as the optimum wavelength in order to determine the protein amount of the COMT 
enzyme isolated from porcine liver used as the enzyme source of this study. Calibration 
curves given in Figure 5.14 were obtained by using the measured absorbance values at 
595 nm of BSA and COMT solutions prepared in 0-16 µg/ml concentrations.  
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Figure 5.14. Calibration curves obtained for proteins 
 
 
By taking into consideration of the ratio of estimated slopes given on calibration 
curves, it was determined that the active protein amount of COMT enzyme was found 
27.7% according to BSA reference protein.  
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5.4. Determination of COMT Activity and Inhibition Kinetics 
 
5.4.1. Activity Determination by Spectrophotometric Method 
 
According to the protocol, by which the COMT enzyme activity was determined 
spectrophotometrically, absorbances of produced the O-methylated forms of DHAP 
were measured at 344 nm. 
 
DHAP + SAM ⎯⎯ →⎯COMT  SAH + 3H4MAP + 4H3MAP  
 
The possible reaction given above was incubated at pH of 7.6 and 37 °C for one hour. In 
the reaction performed in a total volume of 500 µl, while DHAP final concentration was 
fixed at 0.1 mM, varying SAM concentrations were given in Table 5.7. Final 
concentration of 150-unit COMT standard enzyme in the reaction medium was kept 
constant at 0.51 mg solid/ml. Absorbances of test and blank solutions measured at 344 
nm after the reaction was terminated by adding 500 µl of sodium borate at the end of 
one hour were also given in Table 5.7.  
 
Table 5.7. Reaction Medium and Absorbances for Spectrophotometric Method 
Reaction No. SAM Concentration (mM)  Absorbance (344 nm) 
Blank* - 0.481 
Test 1 0.800 0.512 
Test 2 0.160 0.498 
Test 3 0.080 0.492 
Test 4 0.053 0.490 
Test 5 0.040 0.488 
 * According to the protocol, blank solution absorbance value should be between 0.3-0.5. 
 
 
 Enzyme activity was calculated using the mathematical equations defined in the 
applied protocol as following;  
                               
1.0
))(2.126)((
/
ctordilutionfaAAmlUnit blanktest −= ;                       (5.1) 
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mlUnitmgproteinUnit
/
// =                                    (5.2) 
where 126.2 was the conversion factor defined for 1 ml reaction volume and 0.1 was the 
volume of enzyme added to reaction medium (ml). Accordingly, enzyme activities1 
obtained for test solutions were given in Table 5.8.  
 
Table 5.8. Enzyme Activities (spectrophotometric) 
Reaction 
No. 
Unit/ml 
Unit/mg 
protein 
Unit/mg 
solid* 
v (nmol/mg 
protein. min.) 
1/v (nmol/mg 
protein. min.)-1 
Test 1 195.61 276.93 76.70 4.62 ± 0.10 0.22 ± 0.02
Test 2 107.27 151.86 42.06 2.53 ± 0.16 0.39 ± 0.04
Test 3 69.41 98.26 27.21 1.64 ± 0.11 0.61 ± 0.01
Test 4 56.79 80.39 22.27 1.34 ± 0.10 0.75 ± 0.02
Test 5 44.17 62.53 17.32 1.04 ± 0.13 0.96 ± 0.01
* 27.7 % of one mg solid material was taken as active protein (see Bradford method) 
 
 
Reaction velocity (v) and inverse reaction velocity (1/v) values in Table 5.8 were 
analyzed with linear and nonlinear regression analyses performed by using GraphPad 
Prism 5.0 program as explained in 4.2.6. Enzyme Activity and Inhibition Kinetics Data 
Analysis section. The obtained Michaelis and Lineweaver-Burk graphs were given in 
Figure 5.15.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15. A: Michaelis and B: Lineweaver-Burk graphs of spectrophotometrically 
determined enzyme activity  
 
 
1 1 unit of enzyme activity = 1 nmol of O-methylated forms of DHAP produced in one minute per mg of 
protein. 
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Vmax and Km values for this reaction performed in non-inhibitor medium were 
found as 5.69 ± 0.15 nmol/min. mg protein and 0.19 ± 0.01 mM, respectively. Due to 
the fact that, the required amounts of enzyme and substrate in spectrophotometric 
method were quite high and the protocol was developed for reactions performed in optic 
cuvettes causing to consume more time, the inhibition study were performed by 
fluorometric method using 96 well microplates. Since the entire spectrophotometric 
method was a commercial protocol, it was not possible to compare the obtained results 
with the literature. However, by performing this protocol, active protein capacity and 
activity of standard COMT enzyme could be tested.  
 
5.4.2. Determination Activity and Inhibition Kinetics by Fluorometric 
Method 
 
It was known that the results obtained for enzymatic reactions monitored by 
fluorometric method were more sensitive than absorption and less interference was 
observed (Copeland, 2000). Therefore, the protocol modified for determination of 
COMT activity and inhibition kinetics from the studies employed based on fluorometric 
method was applied in this study (Kurkela et al., 2004; Veser, 1987).  
In this method, transformation rate of aesculetin (ES) to scopoletin by COMT 
catalyzed O-methylation reaction and thereby change in fluorescence was measured at 
355 nm excitation and 460 nm emission wavelengths.  
ES + SAM ⎯⎯ →⎯COMT  SAH + Scopoletin 
Total reaction volumes in activity determination and inhibition studies 
performed at 37 °C and pH of 7.4 were determined as 200 µl and 250 µl, respectively.  
 
5.4.2.1. Activity Determination by Fluorometric Method 
 
In the activity determination study by fluorometric method, firstly a linear 
working range for different enzyme and substrate concentrations was found. 
Concentration changes of enzyme and substrates in these reactions were given in Table 
5.9.  
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Table 5.9. Concentration changes of enzyme and substrates 
Enzyme concentrations (µg protein/ml) 
E1 16.5 
E2 11.0 
E3   8.5 
SAM   concentrations (µM) Aesculetin concentrations (µM) 
SAM 1  10 ES1  2 
SAM 2 50 ES2 3 
SAM 3  100 ES3  4 
SAM 4  200 ES4  5 
SAM 5  300 ES5  7 
SAM 6 500 ES6  10 
SAM 7  600   
 
 
In these reactions, which are known to have a total reaction time of 6-8 hours, 
activity was determined by taking the change of fluorescence values between two points 
after reaction progressed at steady state. In order to determine the accurate steady state 
phase of reactions, fluorescent measurements were recorded for 10 hours and kinetic 
data of the sample reaction occurred at the condition of E1-ES3-SAM1 concentrations 
were given in Figure 5.16.  
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Figure 5.16. Product formation kinetics obtained at E1-ES3-SAM1 concentrations      
(10 hours) 
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Based on the kinetic data recorded in 10 hr. time interval given in Figure 5.16, it 
was found adequate to measure the first two hours of fluorescent change for reactions 
catalyzed by COMT. Moreover, fluorescent reduction in the first 20 minutes was a 
characteristic feature of the reaction and the kinetic measurements to be used for 
activity calculations was composed of the values in the first 30 minutes after this period. 
For this purpose, a total two hours of fluorescent measurement obtained for the same 
reaction conditions was given in Figure 5.17.  
 
0,00
5,00
10,00
15,00
20,00
25,00
30,00
35,00
40,00
0 1000 2000 3000 4000 5000 6000 7000 8000
Time (second)
R
el
at
iv
e 
Fl
uo
re
sc
en
ce
 U
ni
t (
R
FU
)
 
 
Figure 5.17. Product formation kinetics obtained at E1-ES3-SAM1 (2 hours) 
 
 
 Kinetic data were obtained for all reactions occurred at every concentration 
values given in Table 5.9, as it was obtained as a result of the reaction given as an 
example in Figure 5.17. Accordingly, it was determined that the measurements recorded 
at the first 30 minute after the 1500th second indicated the ones obtained from steady 
state phase of reactions. Fluorescent change in this 30 min. time interval was 
transformed into enzyme activity data by using the value indicating the effect of one 
nanomole of scopoletin formation on the fluorescence obtained as a result of its 
calibration. Sample calculation of the data transformation and scopoletin calibration 
curve were also given in Appendix C.  
Accordingly, results of the studies, performed in order to determine the linear 
enzyme-substrate concentration range and where the change of the reaction rate 
according to SAM and ES substrates was examined, were given as enzyme activity data 
in Figure 5.18 and 5.19, respectively. 
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Figure 5.18. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different 
enzyme concentrations ([ES] was fixed at 4 µM). 
 
 
 It can be seen from Figure 5.18A, increasing enzyme concentration increased 
reaction rate as expected. However, it is known that in high concentration of SAM 
caused substrate inhibition takes place (Yassin et al., 1998; Veser, 1987). Therefore it 
was observed that the reaction rate obtained at the lowest enzyme concentration E3 (8.5 
µg protein/ml) deviated from linearity (Figure 5.18B). This deviation which was 
thought to be arising from substrate inhibition was slightly observed for rates obtained 
at E2 and E1 concentrations. However, the reaction rate obtained at E2 and E1 
concentrations did not deviated from linearity up to 100 µM SAM concentration as 
given in Figure 5.19.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin up to 100 µM SAM concentrations in presence of different 
enzyme concentrations ([ES] was fixed at 4 µM).        
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enzyme concentration to be used in inhibition study. Moreover, in order to reveal the 
relationship of substrates, reactions, of which the results were given in Figure 5.20 as 
reaction rate data, were performed at fixed E2 concentration while both SAM and ES 
concentrations were varied.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20. A: Michaelis ve B: Lineweaver-Burk graphs of formation rate of scopoletin 
against various ES concentrations in presence of different SAM 
concentrations (enzyme concentration was fixed in 11.0 µg protein/ml 
(E2)) 
 
 
It was observed that the reaction rate increased with the increasing SAM 
concentration and did not deviate from linearity in this concentration range. As a result 
of this study performed in order to determine the enzyme-substrate relationship, Km 
values for SAM and ES were calculated as 3.5 ± 0.3 µM and 6.4 ± 0.4 µM, respectively. 
Km value for aesculetin in Veser, 1987’s study was reported as 6.2 µM. Km values found 
for SAM in several studies have varied according to the used COMT enzyme source 
and difference in the linear concentration ranges. However, it was found that SAM 
which was the methyl donor substrate of COMT catalyzed methylation reaction was the 
rate limiting reactant.  
Based on the results obtained from fluorometric activity tests, it was determined 
that in inhibition studies, the concentrations of both ES and enzyme should be kept at 4 
µM and 11 µg protein/ml, respectively. On the other hand, SAM concentrations were 
varied between the ranges of 10-300 µM.  
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5.4.2.2. Inhibition Study by Fluorometric Method 
 
On the basis of the results obtained for fluorometric activity determination, 
reducing in COMT catalyzed reaction rate was also analyzed fluorometrically by using 
some plant-derived alkaloids, polyphenolics and their standards as inhibitor.  
 
In inhibition study performed in presence of inhibitors given in Table 5.10, 
enzyme kinetic measurements were recorded at 355 nm excitation and 460 nm emission 
wavelengths. Total reaction volume was 250 µl in these experiments performed at 37 °C 
and pH of 7.4. While the SAM concentrations was changed between 10-100 µM for 
first 16 inhibitors given in Table 5.10, its concentration was varied between 10-300 µM 
in studies performed with 17th and 18th inhibitors. 
Among the inhibitors given in Table 5.10, 3,5-DNC was used as positive control 
and the inhibition performances of other inhibitors were compared with that of the 
positive control. The obtained inhibition performances of alkaloid and polyphenolics 
based standards, extracts and fractions at 100 µM SAM concentration were given in 
Figure 5.21 and 5.22. In calculation of inhibition percentages of inhibitors, reaction rate 
obtained at the medium where any inhibitor was present was used as reference rate.   
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Table 5.10. The plant extracts, fractions and their standards used as COMT inhibitors in this study 
 
Inhibitor Name Code Concentration (µg/ml) Inhibitor Name Code Concentration (µg/ml) 
I1a    0.1 I10a 10 
I1b      0.02 I10b   5 
3,5-dinitrocatechol         
(3,5-DNC) 
I1c        0.005 
Oleuropein  
I10c   2 
I2a 5 I11a 10 
I2b 2 I11b   5 Harmol 
I2c    0.5 
Rutin 
I11c   2 
I3a 5 I12a 10 
I3b 2 I12b   5 Harmalol 
I3c    0.5 
Olive (O. europaea) leaf          
crude extract 
I12c   2 
I4a 5 I13a 10 
I4b 2 I13b   5 Harmine 
I4c    0.5 
Fraction rich in Oleuropein        
(FO 1) 
I13c   2 
I5a 5 I14a 10 
I5b 2 I14b   5 Harmaline 
I5c    0.5 
Fraction rich in Rutin and 
glycosides  (FO 5) 
I14c   2 
I6a 5 I15a 10 
I6b 2 I15b   5 Harmal (P. harmala) seed crude extract 
I6c    0.5 
Vitex (V. agnus-cactus) leaf             
crude extract 
I15c   2 
I7a 5 I16a 10 
I7b 2 I16b   5 Harmol and Harmalol fraction (FP 1) 
I7c    0.5 
Cistus (C. parviflorus) leaf             
crude extract 
I16c   2 
I8a 5 I17a 10 
I8b 2 I17b   5 
Harmine fraction (FP 
2) 
I8c    0.5 
Terebinth (P. terebinthus) leaf         
crude extract 
I17c   2 
I9a 5 I18a 10 
I9b 2 I18b   5 Harmaline fraction (FP 3) 
I9c    0.5 
Mastic (P. lentiscus) leaf              
crude extract 
I18c   2 
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Figure 5.21. Inhibition percentages of alkaloid standards, extracts and fractions 
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Figure 5.22. Inhibition percentages of polyphenolic standards and extracts and fractions 
 
 
As it can be seen from Figures 5.21 and 5.22, inhibition performances of 
alkaloid and polyphenolic standards, extracts and fractions used in this study were 
compared to that of positive control, 3,5-DNC which is the best known COMT 
inhibitor. Accordingly, while it was found that inhibition performance of 3,5-DNC was 
100 times higher than those of especially harmine and harmaline alkaloid standards and 
fractions, 3,5-DNC demonstrated about 200 and 300 times higher inhibitory effect than 
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those of polyphenolics when taking into consideration the concentration ranges of 
inhibitors. 
Although their performances were not found as effective as positive control, it 
was revealed that inhibitors coded as I6 (P. harmala-harmal), I16 (C. parviflorus-
cistus), I17 (P. terebinthus-terebinth) and I18 (P. lentiscus-mastic) crude extracts 
demonstrated quite high reducing effect against the COMT catalyzed reaction rate. 
Moreover, it was observed that as a result of the characterization of P. harmala 
seed crude extract, harmine and harmaline alkaloids were the major alkaloids present in 
crude extract. Therefore, it was thought that these major alkaloids in harmal seed were 
the compounds responsible for inhibition when similarities in the inhibition 
performances of crude extract (I6) and its harmine (I8) and harmaline (I9) fractions 
were also taking into consideration.  
In order to explain the inhibition mechanism of each inhibitor used in this study, 
the mathematically derived enzyme inhibition kinetics model equations were used as 
mentioned before in experimental section. The results of the most statistically 
appropriate model, fitted to the experimental enzyme activity data obtained in presence 
of 18 different inhibitors, were given as graphically from Figure 5.23 to Figure 5.40.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.23. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I1 
(3,5-DNC) concentrations ([E] and [ES] were fixed at 11.0 µg protein/ml 
and 4 µM, respectively) 
 
 
As reported in Bonifacio et al., 2007’s study, it is known that almost all 
nitrocatecholics are the tight binding and uncompetitive inhibitors of COMT enzyme. 
As it can be seen from Figure 5.23B, 3,5-DNC which was used as positive control in 
this study was found as a COMT inhibitor with uncompetitive behavior in good 
accordance with literature. The presence of 3,5-DNC even in its low concentrations in 
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the reaction medium caused a very high reduction in scopoletin formation rate (v). As a 
result of the experimental data analyzed by GraphPad program, Km and Vmax kinetic 
constants were calculated as 6.83±0.77 µM and 1.07±0.02 nmol/min. mg protein, 
respectively. Inhibition constant (αKi) given in rate equation (Equation 2.6) derived for 
uncompetitive inhibition was found 9.17±0.46 ng/ml (in other words; 45.60±2.29 nM) 
for 3,5-DNC. Also, the 50% inhibitory concentration (IC50) of 3,5-DNC was found 
44.18±0.78 nM which was in good accordance with the value reported as 35 nM in the 
literature (Kurkela et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.24. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I2 
(harmol standard) concentrations ([E] and [ES] were fixed at 11.0 µg 
protein/ml and 4 µM, respectively) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I3 
(harmalol standard) concentrations ([E] and [ES] were fixed at 11.0 µg 
protein/ml and 4 µM, respectively) 
 
 
Graphical demonstrations of the experimental data obtained with standards of 
harmol and harmalol alkaloids which were the minor alkaloids present in harmal seed 
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were given in Figures 5.24 and 5.25, respectively. COMT inhibition mechanisms of 
these two alkaloids which are structurally similar to each other exhibited also similarity 
with each other and the positive control. As can be seen from Lineweaver-Burk graphs, 
it was determined that harmol and harmalol alkaloids were uncompetitive inhibitors of 
COMT.  
As a result of the reactions performed in the presence of harmol and harmalol 
alkaloids, Km and Vmax kinetic constants were calculated respectively as 6.97±0.89 µM 
and 1.06±0.03 nmol/min. mg protein for harmol and 6.93±0.64 µM and 1.08±0.02 
nmol/min. mg protein for harmalol. Inhibition constant (αKi) of harmol was found 
2.52±0.16 µg/ml while it was calculated as 3.21±0.16 µg/ml for harmalol. As well as 
the kinetic constants were very close to each other, the IC50 values of harmol and 
harmalol were found very similar and calculated as 2.79±0.22 µg/ml (=10.31±0.46 µM) 
and 3.59±0.37 µg/ml (=13.19±0.31 µM), respectively. Accordingly, it was revealed that 
harmol alkaloid can partially be a better inhibitor than harmalol.  
Data analysis graphs obtained for harmine and harmaline alkaloids found 
dominantly in harmal seed were given in Figure 5.26 and 5.27. Inhibition mechanisms 
of these alkaloids which are structurally different from harmol and harmalol but similar 
to each other were also found different from harmol and harmalol alkaloids.  
 
 
 
 
 
 
 
 
   
 
 
 
Figure 5.26. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I4 
(harmine standard) concentrations ([E] and [ES] were fixed at 11.0 µg 
protein/ml and 4 µM, respectively) 
 
 
As it can be seen from Figure 5.26B, the data obtained in presence of harmine 
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Ki and αKi values which indicate the competitiveness and noncompetitiveness were 
found as 0.18±0.07 µg/ml and 1.18±0.08 µg/ml, respectively. Value of α constant was 
calculated as 6.56±0.81 in the presence of harmine alkaloid. Km ve Vmax kinetic 
constants were also calculated as 5.75±1.21 µM and 1.03±0.04 nmol/min. mg protein, 
respectively. Besides, IC50 value of harmine alkaloid was found 0.75±0.09 µg/ml, or in 
other words 3.55±0.16 µM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.27. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I5 
(harmaline standard) concentrations ([E] and [ES] were fixed at 11.0 µg 
protein/ml and 4 µM, respectively) 
 
 
Also in the inhibition kinetics data analysis performed for harmaline standard 
given in Figure 5.27B, mixed type inhibition model was determined as the most 
appropriate model as it was found for harmine. Inhibition constants of harmaline 
standard, Ki and αKi values were calculated respectively as 0.19±0.04 µg/ml and 
1.36±0.11 µg/ml. α constant was found somewhat higher than that of found for harmine, 
as 7.16±0.78. Accordingly, it was revealed that the noncompetitive feature of harmine 
was higher due to having lower α value. However, harmine and harmaline alkaloids did 
not demonstrate too different behaviors from each other. Moreover, IC50 value was 
found as 0.98±0.12 µg/ml, in other words, 4.57±0.14 µM for harmaline alkaloids. Km 
and Vmax kinetic constants in presence of harmaline were calculated respectively as 
5.92±0.87 µM and 1.05±0.02 nmol/min. mg protein.  
As a result of the studies performed with alkaloid standards, the COMT 
inhibition performances of harmine and harmaline alkaloids was found higher than 
those of harmol and harmalol. Despite the fact that harmine and harmaline were the 
inhibitors behaving in very similar mixed type manner, according to results obtained for 
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standards, COMT inhibitory effect of harmine alkaloid was found the highest. In the 
light of these results, inhibition performances of harmal seed crude extract and its 
fractions were analyzed and compared with their corresponding standards. The data 
obtained in presence of harmal seed crude extract in reaction medium were 
demonstrated graphically in Figure 5.28.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.28. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I6 
(harmal seed crude extract) concentrations ([E] and [ES] were fixed at 11.0 
µg protein/ml and 4 µM, respectively) 
 
 
According to the results, the COMT inhibition performance of the crude alkaloid 
extract was found as effective as harmine and harmaline which were the major alkaloids 
exist in the extract, and its mechanism could be explained in a similar manner with that 
of the standards. As it can be seen from Figure 5.28B, crude extract behaved as mixed 
type inhibitor and the inhibition constants, Ki and αKi were calculated respectively as 
0.12±0.02 µg/ml and 2.24±0.75 µg/ml having α value of 18.72±2.28. The higher α 
value of crude extract compared to that of harmine and harmaline alkaloids caused to 
shift the mechanism to competitive inhibition as it can be seen from the Lineweaver-
Burk graph (Figure 5.28B). IC50 concentration of crude extract was found 1.09±0.33 
µg/ml while Km and Vmax were calculated as 6.05±0.69 µM and 1.06±0.02 nmol/min. 
mg protein, respectively. According to the results obtained in the presence of crude 
extract, a partial increase in Km value was observed and it was thought this increase 
arises from the increase in competitiveness. 
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Figure 5.29. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I7 
(harmal seed fraction no FP1) concentrations ([E] and [ES] were fixed at 
11.0 µg protein/ml and 4 µM, respectively) 
 
 
Results of the inhibition studies performed with fractions of harmal seed 
alkaloids was found compatible with that of their corresponding standards. Data 
analysis results obtained for the harmal seed fraction which was characterized as rich in 
harmol and harmalol alkaloids were given graphically in Figure 5.29. Similar to the 
results obtained for harmol and harmalol standards given in Figures 5.24 and 5.25, it 
was observed that harmal fraction coded as FP1 inhibited COMT uncompetitively. The 
αKi and IC50 values for FP1 fraction were calculated as 1.66±0.09 µg/ml and 1.74±0.13 
µg/ml, respectively.  
Accordingly, it was thought that the alkaloids being together might have a 
synergistic effect on the COMT inhibition performance of FP1 fraction which was 
observed to be more effective compared to harmol and harmalol standards. Km and Vmax 
values in the presence of FP1 fraction was calculated as 6.44±0.82 µM ve 1.05±0.02 
nmol/min. mg protein, respectively. 
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Figure 5.30. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I8 
(harmal seed fraction no FP2) concentrations ([E] and [ES] were fixed at 
11.0 µg protein/ml and 4 µM, respectively) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.31. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I9 
(harmal seed fraction no FP3) concentrations ([E] and [ES] were fixed at 
11.0 µg protein/ml and 4 µM, respectively) 
 
 
As a result of the HPLC analyses, it was found that harmal fraction coded as FP2 
consisted of 77% of harmine and 23% of harmaline. Therefore, as a result of inhibition 
experiments performed with the FP2 fraction, it was observed that presence of harmine 
and harmaline together has no effect on inhibition mechanism and it was defined as 
mixed type inhibitor (Figure 5.30) like its corresponding standards. However, as it was 
observed for fraction FP1, presence of harmine and harmaline together provided a 
partially increasing effect on inhibition performance. Ki and αKi values, found 
respectively as 0.18±0.07 µg/ml and 1.18±0.08 µg/ml for harmine standard, were 
calculated as 0.15±0.07 µg/ml and 1.28±0.06 µg/ml for FP2 fraction which was rich in 
harmine. The IC50 value of FP2 fraction was found lower than the harmine standard, as 
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0.69±0.03 µg/ml. Also, Km and Vmax constants were calculated as 5.61±1.68 µM ve 
1.03±0.05 nmol/min. mg protein, respectively. 
Data analysis obtained for FP3 fraction having 93.3% harmaline content was 
graphically demonstrated in Figure 5.31. In accordance with the results obtained for 
harmine and harmaline standards, inhibition performance of FP3 fraction rich in 
harmaline was found lower than that of FP2 fraction. However, inhibition mechanism 
for this fraction was also determined as mixed type, as seen from Figure 5.31B. For the 
FP3 fraction, Ki and αKi values were calculated as 0.23±0.05 µg/ml and 1.47±0.08 
µg/ml, respectively. The α and IC50 values were found to be very close to those of 
harmaline standard and calculated respectively as 6.39±1.08 and 1.10±0.07 µg/ml.  
In inhibition study, it was previously mentioned that the other plant species 
examined with its fractions and comparing with its corresponding standards was olive 
leaf rich in polyphenolics. It was observed that the olive leaf polyphenolics of which 
inhibition performances were found lower than alkaloids when they were compared to 
that of 3,5-DNC. However, in order to illuminate the inhibition mechanisms of 
polyphenolics, the experimental data of them were also been attempted to be explained 
by Michaelis approach.  
Oleuropein, as given in the characterization results of this study, was a 
polyphenol found dominantly in olive leaf. In this respect, COMT inhibition mechanism 
of oleuropein standard was examined firstly. Results obtained for oleuropein standard 
were given graphically in Figure 5.32. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.32. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I10 
(oleuropein standard) concentrations ([E] and [ES] were fixed at 11.0 µg 
protein/ml and 4 µM, respectively) 
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The uncompetitive nature of oleuropein can be seen from Figure 5.32B and 
inhibition constant (αKi) was found 22.96±1.39 µg/ml. However as it can be seen from 
Figure 5.32A, for the used concentration range of oleuropein, 50% inhibition of COMT 
activity could not achieved. Therefore IC50 value could not be calculated for oleuropein 
standard. Km and Vmax kinetic constants in the presence of oleuropein were calculated as 
5.74±0.39 µM and 1.03±0.01 nmol/min. mg protein, respectively. Results of the 
inhibition experiments performed with the standard of rutin which was the secondary 
dominant polyphenol in olive leaf extract were given in Figure 5.33.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.33. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I11 
(rutin standard) concentrations ([E] and [ES] were fixed at 11.0 µg 
protein/ml and 4 µM, respectively) 
 
 
Oleuropein and rutin which are structurally similar polyphenolics was found as 
uncompetitive inhibitors of COMT (Figures 5.32B and 5.33B). However rutin standard 
demonstrated higher inhibitory effect than oleuropein in the same concentration range. 
Inhibition constant, αKi was found as 6.58±0.39 µg/ml for rutin standard; in other 
words, it was 10.78±0.52 µM. In Gugler et al., 1973’s study, similar to this study, 19 
flavonoids were scanned in order to reveal their COMT enzyme inhibition 
performances. Among these, quercetin and rutin were reported as the flavonoids with 
highest inhibitory effect.  
Moreover, in the same study inhibition constants for quercetin and rutin were 
found respectively as 5.3 and 10.8 µM. This value was almost exactly compatible with 
that of rutin calculated in this study. However, in Gugler et al., 1973’s study, it was 
argued that rutin and quercetin inhibit COMT in competitive manner. It was thought 
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that the difference in the obtained results arises from the differences in the used methyl 
acceptor substrates and also in analysis methods.  
Furthermore, IC50 value for rutin standard was found close to the values 
calculated for harmol and harmalol alkaloids, as 7.17±0.81 µg/ml (=11.75±0.93 µM). 
Km and Vmax kinetic constants in the presence of rutin were respectively found as 
6.05±0.79 µM ve 1.03±0.02 nmol/min. mg protein.  
Based on the results of the characterization of olive leaf extract, it was estimated 
that the results of the inhibition study performed with olive leaf crude extract would be 
rather similar to that of oleuropein standard. As it can be seen in the graphical 
demonstration of results obtained for olive leaf crude extract given in Figure 5.34, 
inhibition mechanism and performance were found much closer to those of oleuropein 
standard as expected.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.34. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I12 
(olive leaf crude extract) concentrations ([E] and [ES] were fixed at 11.0 
µg protein/ml and 4 µM, respectively) 
 
 
Inhibition constant (αKi) of the olive leaf crude extract, which was observed to 
inhibit COMT uncompetitively like oleuropein and rutin standards, was found as 
18.51±2.05 µg/ml. For the crude extract which demonstrated a more effective inhibition 
character than oleuropein but lower rutin, IC50 value could not be calculated as for 
oleuropein standard. In the presence of crude extract, Km and Vmax kinetic constants 
were found 5.83±0.83 µM and 1.01±0.03 nmol/min. mg protein, respectively. 
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Figure 5.35. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I13 
(olive leaf fraction no FO1) concentrations ([E] and [ES] were fixed at 
11.0 µg protein/ml and 4 µM, respectively)  
 
 
As a result of the HPLC analyses of the fraction numbered FO1 obtained from 
olive leaf extract, it was found that FO1 fraction was consisted of 91% of oleuropein 
and a little amount of an unidentified polyphenol which was less polar than oleuropein. 
As it can be seen from Figure 5.35B, oleuropein rich FO1 fraction exhibited 
uncompetitive inhibition behavior similar to oleuropein and rutin standards and also 
olive leaf raw extract. However, contrary to expected, FO1 fraction demonstrated much 
higher inhibitory effect than oleuropein and crude extract. This result was thought to be 
arising from the possibility that the presence of unidentified polyphenol present and 
oleuropein together in the fraction FO1 can create positive outcomes regarding their 
inhibitory activities. Inhibition constant (αKi) and IC50 value of FO1 fraction was 
calculated as 4.14±0.28 µg/ml and 4.09±0.16 µg/ml, respectively. Also, in presence 
FO1 fraction, Km and Vmax kinetic constants were found as 6.29±1.07 µM and 
1.04±0.03 nmol/min. mg protein, respectively. 
Furthermore, inhibition kinetic data obtained for the rutin and other glycosides 
especially verbascoside rich fraction of olive leaf extract coded as fraction FO5 were 
given in Figure 5.36.  
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Figure 5.36. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I14 
(olive leaf fraction no FO5) concentrations ([E] and [ES] were fixed at 
11.0 µg protein/ml and 4 µM, respectively) 
 
 
Inhibition mechanism of polyphenolic FO5 fraction could be explained with 
uncompetitive behavior as in other polyphenolic standard, extract and fractions of olive 
leaf (Figure 5.36B). This fraction which dominantly included rutin and verbascoside 
showed higher inhibition effect than the rutin standard. Inhibition constant for this 
fraction (αKi) and IC50 values were calculated as 5.08±0.43 µg/ml and 5.21±0.26 µg/ml, 
respectively. Km and Vmax kinetic constants were found respectively as 5.98±1.21 µM 
and 1.03±0.04 nmol/min. mg protein in the presence of FO5 fraction. 
Despite the COMT inhibitory potentials of crude extracts obtained from olive 
leaf and harmal seeds were increased via fractioning, it was revealed that some 
compounds present in the fractions may create synergistic effect on each other and 
thereby on their inhibitory activities. The crude extracts of other plant species were also 
used in inhibition study without fractioning. Inhibition kinetics data obtained for crude 
extract of vitex leaf among these plants were graphically given in Figure 5.37.  
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Figure 5.37. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I15 
(vitex leaf crude extract) concentrations ([E] and [ES] were fixed at 11.0 
µg protein/ml and 4 µM, respectively) 
 
 
As it can be seen from Figure 5.37B, vitex leaf crude extract demonstrated a 
mixed type inhibition behavior like harmal seed crude extract and its harmine and 
harmaline fractions. Ki and αKi values obtained for vitex leaf crude extract were 
calculated as 4.43±0.89 µg/ml and 9.48±0.58 µg/ml, respectively. For this extract, a 
lower α value was found than those of harmine and harmaline fractions and their 
corresponding standards. Vitex leaf crude extract was found an inhibitor of which the 
noncompetitiveness was higher than that of alkaloids due to having α value of 
2.14±0.23. However, IC50 value was calculated higher than those of alkaloids, as 
12.96±0.29 µg/ml. Therefore, despite noncompetitiveness of vitex leaf crude extract 
was higher, it was revealed that inhibition performance of it were lower than those of 
harmal seed crude extract and its fractions. 
It is known that the vitex leaf crude extract includes some first generation 
COMT inhibitors such as gallic acid, hydroxybenzoic acid, rutin and ferulic acid and 
also some estrogenic compounds like linoleic acid and halimane, labdane type 
diterpenes (Ono et al., 2008; Proestos et al., 2006). In this respect, it was thought that it 
is very critical to inhibit the COMT activity of which an adverse effect on estrogenic 
metabolism is known by plant extracts which consists of estrogenic compounds such as 
vitex leaf extract. 
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Figure 5.38. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I16 
(cistus leaf crude extract) concentrations ([E] and [ES] were fixed at 11.0 
µg protein/ml and 4 µM, respectively) 
 
 
COMT inhibition by the cistus leaf crude extract, which is known to have high 
terpenoids and flavonoids content as it is vitex leaves, could be observed in the 
concentration range used in this study (Somoza et al., 1996). As it can be seen from the 
graphical results obtained for cistus leaf crude extract and given in Figure 5.38, COMT 
enzyme activity inhibited by mixed type inhibition mechanism in the presence of cistus 
leaf crude extract. Inhibition constants indicating competitiveness and 
noncompetitiveness, (Ki and αKi) of cistus leaf crude extract were calculated as 
2.51±0.54 µg/ml and 1.99±0.35 µg/ml, respectively. As it was found for this extract 
vitex leaf crude extract, a lower α value was also found for this extract than those of 
alkaloids. It was revealed that the noncompetitiveness of cistus leaf crude extract was 
the highest due to having α value of 0.79±0.32 which is the closest value to 1. 
Moreover, IC50 value for cistus leaf crude extract was found 2.44±0.09 µg/ml and was 
very close to those of alkaloids. In presence of cistus leaf crude extract, Km and Vmax 
constants were calculated as 6.02±1.29 µM and 1.06±0.04 nmol/min. mg protein, 
respectively. 
It is also known that the cistus leaf crude extract, which demonstrated a 
comparable COMT inhibition performance with those of alkaloids, has vasodilator and 
relaxant effects due to its high terpenoids and flavonoids contents like vitex leaves 
(Somoza et al., 1996). Additionally, it is known that the cistus leaf includes some 
terpenoid volatile oils such as carvacrol, thymol, manoil oxides and esters such as 
benzyl benzoate (Angelopoulou et al., 2001). 
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In this study, COMT enzyme inhibition studies were also performed with crude 
extracts of two Pistacia species known as terebinth and mastic, and the obtained results 
were respectively given in Figures 5.39 and 5.40. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.39. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I17 
(terebinth leaf crude extract) concentrations ([E] and [ES] were fixed at 
11.0 µg protein/ml and 4 µM, respectively)  
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.40. A: Michaelis and B: Lineweaver-Burk graphs of formation rate of 
scopoletin against various SAM concentrations in presence of different I18 
(mastic leaf crude extract) concentrations ([E] and [ES] were fixed at 11.0 
µg protein/ml and 4 µM, respectively) 
 
 
As it can be seen from Figures 5.39B and 5.40B, extracts obtained from 
terebinth and mastic leaves demonstrated mixed type inhibition character as in other 
polyphenolic plant leaves and harmal seed extracts except olive leaf. The αKi values 
were calculated respectively as 3.95±0.37 µg/ml and 3.52±0.61 µg/ml for terebinth and 
mastic crude extracts having respectively α values of 1.37±0.49 and 1.35±0.54 which 
were found to be very close to one and each other. IC50 values for these two Pistacia 
species, of which indicate lower inhibition character than cistus leaf crude extract, were 
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also found very effective and close to each other. These were calculated as 4.40±0.28 
µg/ml and 3.69±0.32 µg/ml for terebinth and mastic leaf crude extracts, respectively. In 
presence of terebinth leaf crude extract, while Km and Vmax kinetic constants were 
respectively found as 6.79±0.86 µM and 1.10±0.04 nmol/min. mg protein, kinetic 
constants in the presence of mastic leaf crude extract were calculated as 6.76±0.93 µM 
and 1.08±0.02 nmol/min. mg protein, respectively. 
As for cistus leaf crude extract, COMT inhibitory effects of terebinth and mastic 
leaf crude extracts were observed as comparable as with those of alkaloids. It has been 
reported in the literature that in the leaves of these two Pistacia species, apigenin, 
luteolin, quercetin, gallic acid and and some anthocyanidins are present (Topcu et al., 
2007; Benhammou et al., 2008). Therefore, it was thought that the high COMT 
inhibitory potentials of Pistacia species can be arise from the fact that they include 
these compounds which are also known as the first generation COMT inhibitors.  
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CHAPTER 6 
 
CONCLUSIONS 
 
 As a result of this study, it was first observed that harmal seed and olive leaf 
demonstrated to have inhibition potencies against COMT enzyme activity with the help 
of their alkaloids and polyphenolics content. In this study, it was mainly focused on 
COMT inhibition performances of harmol, harmalol, harmine and harmaline alkaloids 
found in harmal seed, and oleuropein and rutin polyphenols present in olive leaf. By 
means of extraction and fractionation, it was tried to obtain high yield extracts from 
plant sources and their purities were attempted to be increased in order to determine the 
compounds that were responsible for COMT inhibition. Additionally, COMT enzyme 
inhibition performances of extracts obtained from vitex, cistus, terebinth and mastic 
leaves were examined. 
 Firstly, harmal seed was subjected to different extraction methods. By means of 
HPLC analyses, effects of parameters such as temperature, pH, extraction time and 
solvent type on alkaloid extraction efficiency were investigated. Accordingly, extraction 
process performed with Soxhlet apparatus was determined as the method resulted with 
the highest efficiency. In this method, powdered seeds were extracted with Soxhlet 
apparatus for 7.5 hours in 70°C in which methanol was used as extraction solvent. The 
extract obtained in methanol was dissolved in 2 % of hydrochloric acid solution after 
removal of methanol. Acidic part of the extract, which was subjected twice to liquid-
liquid extraction with petroleum ether, was collected. pH value of the collected solution 
was adjusted to 10 by adding ammonium hydroxide. The extract solution at elevated pH 
values was subjected to liquid-liquid extraction with chloroform for four times. Finally, 
crude alkaloid extract was obtained by collecting the chloroform parts. As a result of the 
HPLC analytical column analysis, trace amount of harmol and harmalol alkaloids were 
found in the crude alkaloid extract while harmine and harmaline contents of the extract 
were calculated as 41% and 58%, respectively. Alkaloid extraction efficiency was found 
also compatible with the literature, as 6.63 %. 
Solvent extraction method was used in order to obtain olive leaf extract. 
Extraction process, in which 70 % of aqueous ethanol solution was used as solvent, was 
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performed in 25°C and 250 rpm for 2 hours using solid/liquid ratio of 1/20. According 
to the HPLC analytical column analysis results of the obtained extract, it was observed 
that one gram of olive leaf dominantly includes 92.50 mg of oleuropein and 9.12 mg of 
rutin. Moreover, it was also observed that minor amounts of polyphenolics such as 
verbascoside, luteolin 7-glycoside are present in olive leaf extract. Besides, leaves of 
plants such as vitex, cistus, terebinth and mastic used as inhibitors in this study were 
also extracted by applying the process optimized for olive leaf.  
Crude alkaloid extract obtained from harmal seed was collected into 3 fractions 
by using semipreparative column in HPLC system and with the help of fractionation 
unit compatible to this system. The purities of 2 major fractions of these, harmine and 
harmaline fractions were determined by HPLC analytical column. Accordingly, 77% of 
the part collected as harmine fraction was found as harmine and nearly 23% of it was 
characterized as harmaline. It was also found that the harmaline fraction includes 93% 
of harmaline and nearly 7% of harmine. 
Fractionation of the olive leaf extract was performed by using silk fibroin 
packed column. Among the parts collected as a total of six fractions, only 2 fractions of 
them, one of which eluted with water was rich in oleuropein and other eluted with 
ethanol was found rich in rutin and other glycosides, were used in inhibition studies. 
Oleuropein content of the water fraction was determined as 91% according to the HPLC 
analyses. In the ethanol fraction, it was revealed that rutin and verbascoside content has 
great majority. 
Before the inhibition studies, the active protein amount of COMT enzyme was 
determined. In this study, which was performed according to the Bradford protein 
determination method, active protein amount of COMT enzyme was found as 27.7 % 
with respect to BSA that was reference protein. COMT enzyme activity was examined 
both spectrophotometrically and fluorometrically and it was revealed that the 
fluorometric activity determination method was more accurate and economical 
compared to absorbance. In the fluorometric activity determination study, formation 
kinetics of scopoletin was followed and firstly, linear operation concentration ranges for 
COMT enzyme and for both substrates SAM and aesculetin was tried to be determined. 
According to the results of this study, enzyme and aesculetin concentrations were fixed 
at 11 µg protein/ml and 4 µM, respectively in the inhibition experiments. It was 
revealed that SAM which is the rate limiting substrate demonstrated inhibitory feature 
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at its concentrations of higher than 100 µM. Km values for SAM and aesculetin were 
calculated as 3.5 ± 0.3 µM and 6.4 ± 0.4 µM, respectively. 
In the study, where basically inhibition performances of extracts and fractions 
obtained from harmal seed and olive leaf on COMT enzyme were examined, 3,5-DNC 
was used as reference inhibitor. Apart from that, performances of 17 inhibitors 
including alkaloid and polyphenolic standards, extracts and fractions were tested. While 
it was found that inhibition performance of 3,5-DNC, which is the best known 
uncompetitive inhibitor of COMT, was 100 times higher than especially harmine and 
harmaline alkaloid standards and fractions, it demonstrated 200 and 300 times 
inhibitory effect than polyphenolics. 
Taking into consideration the concentration ranges of inhibitors, despite it was 
observed that their performances were not as effective as positive control, the inhibition 
percentages of extracts obtained from harmal seed and from vitex, terebinth and mastic 
leaves were found quite high. While the inhibition mechanisms for major alkaloids 
present in harmal seed were explained with the mixed type model, it was determined 
that in the presence of standards, extracts and fractions of olive leaf polyphenolics, 
uncompetitive inhibition occurred. On contrary to that, polyphenolic extracts of the 
other four plants behaved as mixed type inhibitors similar to major alkaloids. 
In this study, crude extract of the harmal seed, which was one the plant source of 
which the inhibition performances of both extract and their fractions were examined 
together, and its harmine and harmaline rich fractions demonstrated the highest 
inhibition among the other plant species and were found very close to each other. This 
result obtained was found in good accordance with HPLC analysis results and it was 
revealed that the high inhibitory effect of harmal seed extract arises from its harmine 
and harmaline content. Concentration values (IC50) of the alkaloids where 50 % 
inhibition occurs were found between 0.69 and 1.10 µg/ml. Among these, harmine 
fraction showed the highest inhibition percentage compared to those of other alkaloid 
fractions, crude alkaloid extract and its own standard. Competitiveness and 
noncompetitiveness inhibition constants (Ki and αKi) of the harmine fraction which was 
found to be a mixed type inhibitor were calculated as 0.15±0.07 µg/ml and 1.28±0.06 
µg/ml, respectively. 
According to the results of the inhibition experiments performed with standards, 
crude extract and fractions of olive leaf polyphenolics, water fraction rich in oleuropein 
was found to have the highest inhibitory effect. Inhibition constant (αKi) of this fraction, 
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which was determined as an uncompetitive inhibitor of COMT, and its IC50 value were 
calculated as 4.14±0.28 µg/ml and 4.09±0.16 µg/ml, respectively. This result, contrary 
to expected, was found very different from those of oleuropein standard and olive leaf 
crude extract. It was thought that the presence of compounds together may have both 
positive and sometimes negative effects on their specific biological activities. Thus, the 
importance of fractioning had been understood. 
As a more general conclusion, it is known that today synthetic COMT inhibitors 
are still used in the treatment of Parkinson disease. It was determined that plant derived 
compounds have great potential to replace with their synthetic derivatives. Especially, it 
was revealed that harmal seed alkaloids and olive leaf fractions are promising natural 
COMT inhibitors. Moreover, it is known that these alkaloid and polyphenolics based 
natural compounds have the possibility to be functionally used in food and cosmetics 
industries because of their antioxidant and antimicrobial features. 
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APPENDIX A 
 
CALIBRATION CURVES OF ALKALOIDS                           
AND SAMPLE CALCULATION 
 
It has been determined with High Performance Liquid Chromatography (HPLC) 
analyses that harmol, harmalol, harmine and harmaline are the major alkaloids present 
in the extract obtained from harmal seed. Calibration curves have been obtained with 
their standards in order to determine the quantifications of these alkaloids. For 
calibration of each standard alkaloid, concentrations given in section 5.1.1.-Table 5-3 
have been used. Peak areas in the chromatograms obtained with HPLC analyses 
performed in these concentrations have been modeled as a linear function of the 
concentration.  
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Figure A1. Harmol calibration curve 
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Figure A2. Harmalol calibration curve 
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Figure A3. Harmine calibration curve 
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Figure A4. Harmaline calibration curve 
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Chromatogram obtained with HPLC analysis performed for the extract diluted 7 
times is given in Section 5.1.1., in Figure 5-1. Accordingly, quantification calculation 
for alkaloids was performed and parameters such as extraction efficiency, alkaloid 
amount in the extract and fractions have been determined as a result of these 
calculations.  
 
Sample Calculation: A total of 165.76 mg extract was solved in 20 ml mobile 
phase and diluted 7 times. After the diluted sample was filtered, it was injected to HPLC 
system with 20 µl of injection volume. As a result of the analysis performed; 
The harmine peak intensity on the chromatogram is integrated and the peak area 
is found as 20829. By using calibration curve equation y=42.476x given in A3, value x 
(concentration, µg/ml) has been calculated. 
4.490
476.42
20829 ==x  µg/ml. This value is multiplied by total volume*dilution 
factor and harmine alkaloid amount in the crude extract has been calculated in terms of 
µg.  
Harmine content (mg harmine/165.76 mg extract) =
1000
7*20*4.490 =68.7 mg 
harmine. As a result of this calculation it has been calculated that the extract includes 
nearly 41% of harmine. Amounts of harmaline, harmol and harmalol alkaloids in the 
extract were determined with the same calculation method. Accordingly, the peak area 
of harmol and harmalol alkaloids in the extract could not be calculated since they were 
below the detection limits. Harmaline content was found as 97.1 mg. Harmaline content 
of crude alkaloid extract was found as 58% in percentage. It is thought that the 
remaining part consists of harmol, harmalol and other unidentified alkaloid derivatives.  
In this extraction method, initially 2500 mg of powdered harmal seed was used. 
At the end of the extraction process, 165.76 mg crude alkaloid extract was obtained. 
Therefore;  
Extraction efficiency was calculated as, mg alkaloid/mg seed (%) = 
2500
100*76.165 = % 
6.63. 
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APPENDIX B 
 
CALIBRATION CURVES OF OLEUROPEIN AND RUTIN                  
AND SAMPLE CALCULATION 
 
As in defining alkaloid amounts in the alkaloid extract, amounts of oleuropein 
and rutin in the olive leaf extract were calculated using peak area values obtained from 
HPLC analysis results. 
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Figure B1. Oleuropein calibration curve 
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Figure B2. Rutin calibration curve 
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Sample Calculation:  
One gram of olive leaf powder is extracted at a solid/liquid ratio of 1/20. 
According to the result of the HPLC analysis of the crude extract obtained with the 
extraction process, oleuropein peak area was calculated as 22815. Using the calibration 
curve equation y=4.9444x-27.108 given in Figure B1, x value (concentration, µg/ml) 
was calculated. 
4624
9444.4
108,2722815 =+=x  µg/ml. This value was multiplied by total 
extraction volume (20 ml) and the amount of oleuropein in one gram of olive leaf has 
been calculated. Accordingly, it was calculated that one gram of olive leaf includes 92.5 
mg oleuropein and according to the similar calculations for rutin, 9.12 mg of rutin. 
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APPENDIX C 
 
CALIBRATION CURVE OF SCOPOLETIN                    
AND SAMPLE CALCULATION 
 
According to fluorometric enzyme activity determination method, aesculetin is 
transformed to scopoletin as a result of COMT catalyzed O-methylation reaction. 
Production rate of scopoletin which has fluorescence feature also by itself, as a result of 
the reaction was measured at 355 nm excitation and 460 nm emission wavelengths. By 
adding different amounts of scopoletin into the reaction medium, an increase in 
fluorescence was achieved and therefore calibration curve was obtained (Figure C1).  
 
y = 309,91x
R2 = 0,9871
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
0 5 10 15 20 25 30
scopoletin amount (nmol)
R
el
at
iv
e 
Fl
uo
re
se
nc
e 
U
ni
t (
R
FU
)
 
 
Figure C1: Scopoletin calibration curve 
 
 
Slope of the calibration curve given in Figure C1 is calculated as 309.91. This 
value indicated that a nanomole scopoletin is identical to 309.91 units of fluorescence 
and it was used in activity calculations.  
 
Sample Calculation: 
For instance, in inhibition experiments performed with fluorometric method, 
blank solution fluorescence change (ΔRFB) was found 20.282 for 30 minutes reaction 
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time interval. In a reaction medium of total 250 µl volume performed in a 96-well plate, 
there is 2.2 µg of protein. Therefore, reaction rate is calculated as; 
9916.0
)0022.0)(30)(91.309(
282.20
)0022.0)(30)(91.309(
==Δ= RFBv  nmole scopoletin /min. mg 
protein  
 
 
